

(19)



(11) Publication number:

**SG 191235 A1**

(43) Publication date:

**31.07.2013**

(51) Int. Cl:

**C12N 9/02, C12N 9/04, C12N  
9/10, C12N 9/88, C12N 9/90,  
C12P 5/00;**

(12)

## Patent Application

(21) Application number: **2013047006**

(71) Applicant:

**DANISCO US INC. 925 PAGE MILL  
ROAD PALO ALTO, CALIFORNIA  
94304-1013 CA US  
THE GOODYEAR TIRE & RUBBER  
COMPANY 200 INNOVATION WAY  
AKRON, OHIO 44316 OH US**

(22) Date of filing: **22.12.2011**

(30) Priority: **US 61/426,505 22.12.2010**

(72) Inventor:

**MUIR, RACHEL, E. 925 PAGE MILL  
ROAD PALO ALTO, CALIFORNIA  
94304-1013 US  
WEYLER, WALTER 925 PAGE MILL  
ROAD PALO ALTO, CALIFORNIA  
94304-1013 US**

(54) **Title:**

**COMPOSITIONS AND METHODS FOR IMPROVED  
ISOPRENE PRODUCTION USING TWO TYPES OF ISPG  
ENZYMES**

(57) **Abstract:**

The invention provides for compositions and methods for producing isoprene by using recombinantly engineered cells that utilize a system of dual IspG enzymes in addition to isoprene synthase.



(51) International Patent Classification:

C12N 9/02 (2006.01) C12N 9/88 (2006.01)  
C12N 9/04 (2006.01) C12N 9/90 (2006.01)  
C12N 9/10 (2006.01) C12P 5/00 (2006.01)

(21) International Application Number:

PCT/US2011/066949

(22) International Filing Date:

22 December 2011 (22.12.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/426,505 22 December 2010 (22.12.2010) US

(71) Applicants (for all designated States except US): **DANISCO US INC.** [US/US]; 925 Page Mill Road, Palo Alto, CA 94303-1013 (US). **THE GOODYEAR TIRE & RUBBER COMPANY** [US/US]; 1144 East Market Street, Akron, OH 44316-0001 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MUIR, Rachel, E.** [US/US]; 925 Page Mill Road, Palo Alto, CA 94303-1013 (US). **WEYLER, Walter** [US/US]; 925 Page Mill Road, Palo Alto, CA 94303-1013 (US).

(74) Agents: **SHIEH-NEWTON, Terri** et al.; Morrison & Forster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: COMPOSITIONS AND METHODS FOR IMPROVED ISOPRENE PRODUCTION USING TWO TYPES OF ISPG ENZYMES




Figure 2

(57) Abstract: The invention provides for compositions and methods for producing isoprene by using recombinantly engineered cells that utilize a system of dual IspG enzymes in addition to isoprene synthase.

COMPOSITIONS AND METHODS FOR IMPROVED ISOPRENE PRODUCTION  
USING TWO TYPES OF ISPG ENZYMES

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority benefit of United States provisional patent application No. 61/426,505, filed on December 22, 2010, the content of which is hereby incorporated by reference herein in its entirety.

FIELD OF THE INVENTION

[0002] The present invention relates generally to compositions and methods for improving the production of isoprene from recombinant cells by utilizing two types of IspG enzymes.

BACKGROUND OF THE INVENTION

[0003] Isoprene (2-methyl-1,3-butadiene) is the critical starting material for a variety of synthetic polymers, most notably synthetic rubbers. Isoprene is naturally produced by a variety of microbial, plant, and animal species. In particular, two pathways have been identified for the biosynthesis of isoprene: the mevalonate (MVA) pathway and the non-mevalonate (DXP) pathway. However, the yield of isoprene from naturally-occurring organisms is commercially unattractive. About 800,000 tons per year of *cis*-polyisoprene are produced from the polymerization of isoprene; most of this polyisoprene is used in the tire and rubber industry. Isoprene is also copolymerized for use as a synthetic elastomer in other products such as footwear, mechanical products, medical products, sporting goods, and latex.

[0004] Currently, the tire and rubber industry is based on the use of natural and synthetic rubber. Natural rubber is obtained from the milky juice of rubber trees or plants found in the rainforests of Africa. Synthetic rubber is based primarily on butadiene polymers. For these polymers, butadiene is obtained as a co-product from ethylene and propylene manufacture.

[0005] While isoprene can be obtained by fractionating petroleum, the purification of this material is expensive and time-consuming. Petroleum cracking of the C5 stream of

hydrocarbons produces only about 15% isoprene. Thus, more economical methods for producing isoprene are needed. In particular, methods that produce isoprene at rates, titers, and purity that are sufficient to meet the demands of a robust commercial process are desirable. Also desired are systems for producing isoprene from inexpensive starting materials. The invention described herein addresses these needs and provides additional benefits as well.

[0006] All publications, patent applications, and patents cited in this specification are herein incorporated by reference as if each individual publication, patent application, or patent were specifically and individually indicated to be incorporated by reference. In particular, all publications cited herein are expressly incorporated herein by reference for the purpose of describing and disclosing compositions and methodologies which might be used in connection with the invention.

#### BRIEF SUMMARY OF THE INVENTION

[0007] The invention provides, *inter alia*, compositions and methods for the production of isoprene in increased amounts using two types of 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate synthase (HDS or IspG) IspG enzymes and/or other DXP pathway nucleic acids and polypeptides, iron-sulfur cluster-interacting redox nucleic acids and polypeptides, and isoprene synthase nucleic acids and polypeptides.

[0008] In one aspect, the invention provides for recombinant cells capable of producing isoprene, the cell comprising (i) a heterologous nucleic acid encoding a first 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate synthase (IspG) polypeptide, or one or more copies of an endogenous nucleic acid encoding an IspG polypeptide, of a first species; (ii) a heterologous nucleic acid encoding a second IspG polypeptide, or one or more copies of an endogenous nucleic acid encoding an IspG polypeptide, of a second species, wherein the second species differs from the first species; (iii) a heterologous nucleic acid encoding at least one additional DXP pathway enzyme; and (iv) a nucleic acid encoding isoprene synthase polypeptide. In another aspect, the invention provides for recombinant cells capable of producing isoprene, the cell transformed with: (i) a nucleic acid encoding a first 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate synthase (IspG) polypeptide of a first species; (ii) a nucleic acid

encoding a second IspG polypeptide of a second species, wherein the second species differs from the first species; (iii) a nucleic acid encoding at least one DXP pathway enzyme and (iv) a nucleic acid encoding an isoprene synthase polypeptide. In any of these aspects, the first IspG is from *T. longatus*. In other aspects, the second IspG is from *E. coli*. In some aspects, the additional DXP pathway enzyme is selected from the group of DXS, DXR, MCT, CMK, MCS, HDR (IspH), and IDI. In some aspects, the additional DXP pathway enzyme can be any one or more of: DXS, DXR, HDR (IspH), and IDI.

**[0009]** In any of the aspects herein, the recombinant cell further comprises a heterologous nucleic acid encoding an iron-sulfur cluster-interacting redox polypeptide or one or more copies of an endogenous nucleic acid encoding an iron-sulfur cluster-interacting redox polypeptide. In some aspects, the iron-sulfur cluster-interacting redox polypeptides are selected from ferredoxons and flavodoxins.

**[0010]** In any of the aspects herein, the recombinant cell further comprises a heterologous nucleic acid encoding a DXP pathway associated polypeptides (e.g., DXP partner proteins) or one or more copies of an endogenous nucleic acid encoding a DXP pathway associated polypeptides (e.g., DXP partner proteins). In certain aspects, the DXP pathway associated polypeptides are selected from chaperonins, included among which are enzymes exhibiting the well known protein-folding and/or re-folding functions as well as enzymes involved in the delivery, maintenance, and/or repair of functional iron-sulfur clusters.

**[0011]** In any of the aspects herein, the recombinant cell further comprises one or more heterologous nucleic acid encoding an isopentenyl-diphosphate delta-isomerase (IDI) polypeptide or one or more copies of an endogenous nucleic acid encoding an IDI polypeptide.

**[0012]** In any of the aspects herein, the recombinant cell further comprises one or more heterologous nucleic acid encoding a MVA pathway polypeptide or one or more copies of an endogenous nucleic acid encoding a MVA pathway polypeptide.

**[0013]** In any of the aspects herein, the isoprene synthase polypeptide is a plant isoprene synthase polypeptide. In any of the aspects herein, the isoprene synthase polypeptide is *P*.

*alba* isoprene synthase. In some aspects, the isoprene synthase polypeptide is a polypeptide from *Pueraria* or *Populus* or a hybrid, *Populus alba* x *Populus tremula*. In other aspects, the isoprene synthase polypeptide is selected from the group consisting of *Pueraria montana* or *Pueraria lobata*, *Populus tremuloides*, *Populus alba*, *Populus nigra*, and *Populus trichocarpa*. In other aspects, the plant isoprene synthase polypeptide is a kudzu isoprene synthase polypeptide. In some aspects, the isoprene synthase polypeptide is a naturally-occurring isoprene synthase polypeptide. In other aspects, the isoprene synthase polypeptide is a non-naturally-occurring isoprene synthase polypeptide. In other aspects, the isoprene synthase polypeptide is an isoprene synthase variant or isoprene synthase mutant as disclosed in WO 2009/041581, US Publ. No. 2010/0003716, WO 2010/0124146 or US Appl. 13/283,564.

**[0014]** In any of the aspects herein, the recombinant cell is a bacterial, algal, fungal or yeast cell. In some aspects, the recombinant cell is a bacterial cell. In some aspects, the bacterial cell is a gram-positive bacterial cell or gram-negative bacterial cell. In some aspects, the bacterial cell is *E. coli*. In other aspects, the bacterial cell is selected from the group consisting of *E. coli*, *P. citrea*, *B. subtilis*, *B. licheniformis*, *B. lentus*, *B. brevis*, *B. stearothermophilus*, *B. alkalophilus*, *B. amyloliquefaciens*, *B. clausii*, *B. halodurans*, *B. megaterium*, *B. coagulans*, *B. circulans*, *B. lautus*, *B. thuringiensis*, *S. albus*, *S. lividans*, *S. coelicolor*, *S. griseus*, *Pseudomonas sp.*, and *P. alcaligenes cells*. In any of the aspects herein, the nucleic acids can be on one or multiple plasmids.

**[0015]** In another aspect, the invention also provides for a cell culture comprising any of the recombinant cells disclosed herein, wherein the cell culture is capable of producing at least about 8.4 g/l of isoprene.

**[0016]** In another aspect, the invention also provides for methods of producing isoprene, the method comprising: (a) culturing any of the recombinant cells disclosed herein under conditions suitable for producing isoprene and (b) producing isoprene. In some aspects, the method further comprises recovering the isoprene. In other aspects, the recombinant cells produce greater than about 8.4 g/l of isoprene.

## BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 depicts a plasmid map of Ptac *Anabaena ispH-T* along *ispG* system *aspA* term/pEWL454. kan – kanamycin antibiotic resistance marker ; p15A ori – plasmid origin of replication; RBS – ribosome binding site. The positions of the Tac promoter, *aspA* terminator, and genes encoding the *IspH* and *IspG* system components are indicated on the map; *Anabaena ispH* encodes 4-hydroxy-3-methylbut-2-enyl diphosphate reductase (*IspH*), *T* along *gcpE* encodes 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate synthase (*IspG*), *T* along *petF* encodes ferredoxin (Fd), and *T* along *petH* encodes ferredoxin-NADP<sup>+</sup> oxidoreductase (Fpr).

[0018] Figure 2 shows a graph of isoprene titer versus time in a 15L scale fermentation of REM F2\_18.

[0019] Figure 3 shows MVA and DXP metabolic pathways for isoprene (based on F. Bouvier *et al.*, Progress in Lipid Res. 44:357-429, 2005). The following description includes alternative names for each polypeptide in the pathways and a reference that discloses an assay for measuring the activity of the indicated polypeptide (each of these references are each hereby incorporated herein by reference in their entireties). **Mevalonate Pathway: AACT**; Acetyl-CoA acetyltransferase, MvaE, EC 2.3.1.9. Assay: J. Bacteriol. 184:2116–2122, 2002; **HMGS**; Hydroxymethylglutaryl-CoA synthase, MvaS, EC 2.3.3.10. Assay: J. Bacteriol. 184:4065–4070, 2002; **HMGR**; 3-Hydroxy-3-methylglutaryl-CoA reductase, MvaE, EC 1.1.1.34. Assay: J. Bacteriol. 184:2116–2122, 2002; **MVK**; Mevalonate kinase, ERG12, EC 2.7.1.36. Assay: Curr Genet 19:9-14, 1991. **PMK**; Phosphomevalonate kinase, ERG8, EC 2.7.4.2, Assay: Mol. Cell. Biol. 11:620–631, 1991; **DPMDC**; Diphosphomevalonate decarboxylase, MVD1, EC 4.1.1.33. Assay: Biochemistry 33:13355-13362, 1994; **IDI**; Isopentenyl-diphosphate delta-isomerase, IDI1, EC 5.3.3.2. Assay: J. Biol. Chem. 264:19169-19175, 1989. **DXP Pathway: DXS**; 1-Deoxyxylulose-5-phosphate synthase, dxs, EC 2.2.1.7. Assay: PNAS 94:12857-62, 1997; **DXR**; 1-Deoxy-D-xylulose 5-phosphate reductoisomerase, dxr, EC 2.2.1.7. Assay: Eur. J. Biochem. 269:4446–4457, 2002; **MCT**; 4-Diphosphocytidyl-2C-methyl-D-erythritol synthase, IspD, EC 2.7.7.60. Assay: PNAS 97: 6451–6456, 2000; **CMK**; 4-Diphosphocytidyl-2-C-methyl-D-erythritol kinase, IspE, EC 2.7.1.148. Assay: PNAS 97:1062-1067, 2000; **MCS**; 2C-Methyl-D-erythritol 2,4-cyclodiphosphate synthase,

IspF, EC 4.6.1.12. Assay: PNAS 96:11758-11763, 1999; **HDS**; 1-Hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate synthase, ispG, EC 1.17.4.3. Assay: J. Org. Chem. 70:9168 -9174, 2005; **HDR**; 1-Hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate reductase, IspH, EC 1.17.1.2. Assay: JACS 126:12847-12855, 2004.

[0020] Figure 4 shows a graph of isoprene titer versus time in individual 15L scale fermentations of REM F2\_18 and REM H8-12.

#### DETAILED DESCRIPTION OF THE INVENTION

[0021] The invention provides, *inter alia*, systems, compositions and methods for the increased production of isoprene by engineering recombinant cells with two types of IspG enzymes, a DXP pathway enzyme, and an isoprene synthase polypeptide such that increased amounts of isoprene can be produced.

#### Definitions

[0022] Unless defined otherwise, the meanings of all technical and scientific terms used herein are those commonly understood by one of skill in the art to which this invention belongs. Singleton, *et al.*, Dictionary of Microbiology and Molecular Biology, 2nd ed., John Wiley and Sons, New York (1994), and Hale & Marham, The Harper Collins Dictionary of Biology, Harper Perennial, N.Y. (1991) provide one of skill with a general dictionary of many of the terms used in this invention. It is to be understood that this invention is not limited to the particular methodology, protocols, and reagents described, as these may vary. One of skill in the art will also appreciate that any methods and materials similar or equivalent to those described herein can also be used to practice or test the invention. The headings provided herein are not limitations of the various aspects or aspects of the invention which can be had by reference to the specification as a whole.

[0023] As used herein, the term "isoprene" or "2-methyl-1,3-butadiene" (CAS# 78-79-5 ) refers to the direct and final volatile C5 hydrocarbon product from the elimination of pyrophosphate from 3,3-dimethylallyl pyrophosphate (DMAPP), and does not involve the linking or polymerization of one or more isopentenyl diphosphate (IPP) molecules to one or



more DMAPP molecules. The term “isoprene” is not generally intended to be limited to its method of production.

[0024] As used herein, the term “polypeptides” includes polypeptides, proteins, peptides, fragments of polypeptides, and fusion polypeptides.

[0025] As used herein, an “isolated polypeptide” is not part of a library of polypeptides, such as a library of 2, 5, 10, 20, 50 or more different polypeptides and is separated from at least one component with which it occurs in nature. An isolated polypeptide can be obtained, for example, by expression of a recombinant nucleic acid encoding the polypeptide. An isolated polypeptide can be a non-naturally occurring polypeptide.

[0026] By “heterologous polypeptide” is meant a polypeptide encoded by a nucleic acid sequence derived from a different organism, species, or strain than the host cell. In some aspects, a heterologous polypeptide is not identical to a wild-type polypeptide that is found in the same host cell in nature.

[0027] As used herein, a “nucleic acid” refers to two or more deoxyribonucleotides and/or ribonucleotides covalently joined together in either single or double-stranded form.

[0028] By “recombinant nucleic acid” is meant a nucleic acid of interest that is free of one or more nucleic acids (*e.g.*, genes) which, in the genome occurring in nature of the organism from which the nucleic acid of interest is derived, flank the nucleic acid of interest. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (*e.g.*, a cDNA, a genomic DNA fragment, or a cDNA fragment produced by PCR or restriction endonuclease digestion) independent of other sequences. In some cases, a recombinant nucleic acid is a nucleic acid that encodes a non-naturally occurring polypeptide.

[0029] By “heterologous nucleic acid” is meant a nucleic acid sequence derived from a different organism, species or strain than the host cell. In some aspects, the heterologous

nucleic acid is not identical to a wild-type nucleic acid that is found in the same host cell in nature.

[0030] As used herein, the phrase, “various nucleic acids and polypeptides associated with the DXP pathway,” or “DXP pathway associated nucleic acid(s) or polypeptide(s)” refers to any nucleic acid or polypeptide that interacts with DXP pathway polypeptides or nucleic acids, including, but not limited to, a terpene synthase (*e.g.*, ocimene synthase, farnesene synthase, and artemesinin synthase), either directly or indirectly.

[0031] For use herein, unless clearly indicated otherwise, use of the terms “a”, “an,” and the like refers to one or more.

[0032] Reference to “about” a value or parameter herein includes (and describes) aspects that are directed to that value or parameter *per se*. For example, description referring to “about X” includes description of “X.” Numeric ranges are inclusive of the numbers defining the range.

[0033] It is understood that aspects and aspects of the invention described herein include “comprising,” “consisting,” and “consisting essentially of” aspects and aspects.

#### *Recombinant Cells Capable of Producing Isoprene*

[0034] As described in greater detail and further exemplified herein, recombinant cells capable of producing isoprene can be engineered for increased isoprene production. As described herein, increased isoprene production can be achieved by recombinant cells capable of producing isoprene comprising (i) a heterologous nucleic acid encoding a first 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate synthase (IspG) polypeptide, or one or more copies of an endogenous nucleic acid encoding an IspG polypeptide, of a first species; (ii) a heterologous nucleic acid encoding a second IspG polypeptide, or one or more copies of an endogenous nucleic acid encoding an IspG polypeptide, of a second species, wherein the second species differs from the first species; (iii) a heterologous nucleic acid encoding at least one additional DXP pathway enzyme; and (iv) a nucleic acid encoding isoprene synthase

polypeptide. In one aspect, the first IspG polypeptide of a first species is from *E. coli*. In another aspect, the second IspG polypeptide of a second species is from *T. elongatus* IspG.

### *IspG Enzymes and Systems*

**[0035]** IspG enzymes are part of the lower DXP pathway. IspG nucleic acids code for 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate synthase (IspG) or HDS polypeptides, which convert 2-C-methyl-D-erythritol 2, 4-cyclodiphosphate (ME-CPP or cMEPP) into (E)-4-hydroxy-3-methylbut-2-en-1-yl-diphosphate (HMBPP or HDMAPP).

**[0036]** Some recombinant cells (e.g., BL21 *E. coli* strain) that have been engineered to utilize the DXP pathway for isoprenoid biosynthesis have IspG activity that is too low to support high yield generation of isoprene from glucose. Thus for commercial production of isoprene, these recombinant cells are not sufficient for generating the commercially relevant levels of isoprene that are needed. Accordingly, the invention provides for compositions and methods for increasing isoprene production by increasing IspG polypeptide activity.

**[0037]** For increasing IspG polypeptide activity, one option is to express more of the endogenous *E. coli* IspG system. The systems, compositions of recombinant cells, and methods described herein utilize a different approach where IspG polypeptide activity and subsequent isoprene production is enhanced by over-expression of two types of IspG polypeptide-encoding nucleic acids. In one aspect, the two types of IspG polypeptides are *E. coli* and *T. elongatus* IspG polypeptides. In some aspects, the IspG polypeptide are encoded by heterologous nucleic acids. In other aspects, the IspG polypeptide are encoded by one or more copies of endogenous nucleic acids that are introduced to the host cell (e.g., *E. coli*). In any of these aspects, the nucleic acids may be introduced to the host cell (e.g., *E. coli*) by one or multiple plasmids. In other aspects, the nucleic acids may be introduced to the host cell (e.g., *E. coli*) by integration into the host cell's chromosome. One of skill in the art would appreciate that integration should occur at a location that is not essential to the host cell. For example, in a bacterial cell (e.g., *E. coli* cell), integration into the origin of replication (or any other essential region of the chromosome) would render the bacteria unable to replicate. Thus, care should be taken to avoid integrating into essential locations of the chromosome in the host organism.

[0038] The *E. coli* IspG system includes, but is not limited to, the enzyme IspG (encoded by the gene *ispG*) and the required flavodoxin redox partner FldA (encoded by the gene *fldA*).

The

*T. elongatus* IspG system includes, but is not limited to, the enzyme IspG (encoded by the gene *gcpE*) and the required ferredoxin redox partner Fd (encoded by the *petF* gene), as well as the nonessential ferredoxin-NADP(+) oxidoreductase redox partner Fpr (encoded by the *petH* gene).

In some instances, Fpr activity is not required for the *T. elongatus* IspG to function within *E. coli* where the activity of the *T. elongatus* IspG was found to be dependent on the Fd cofactor. The *fpr* gene of *E. coli* is nonessential and the activity of the *T. elongatus* IspG within *E. coli* depends on co-expression of the *T. elongatus* Fd.

[0039] Without being bound by theory, the *E. coli* IspG system and the *T. elongatus* IspG system are believed to ultimately obtain the electrons necessary to perform their catalytic function from NADPH via some flavodoxin / ferredoxin-NADP(+) oxidoreductase activity. Enzymes with flavodoxin / ferredoxin-NADP(+) oxidoreductase activity have been demonstrated *in vitro* to fulfill the role of electron transport to the required flavodoxin and ferredoxin cofactors essential for IspG activity, however the *in vivo* physiological relevance of these reductases has not been shown and, as such, cannot be predictable.

#### *Exemplary Polypeptides and Nucleic Acids*

[0040] As noted above, recombinant cells of the invention and their progeny are engineered to have two types of IspG enzymes, isoprene synthase and one or more other DXP pathway polypeptide(s). In some aspect, the cell can further contain various iron-sulfur cluster-interacting redox polypeptides and nucleic acids, MVA pathway polypeptides and nucleic acids, DXP pathway associated polypeptides (e.g., DXP partner proteins) and nucleic acids, PGL polypeptides and nucleic acids and IDI polypeptides and nucleic acids.

[0041] Polypeptides includes polypeptides, proteins, peptides, fragments of polypeptides, and fusion polypeptides. In some aspects, the fusion polypeptide includes part or all of a first polypeptide (e.g., an iron-sulfur cluster-interacting redox polypeptide, DXP pathway polypeptide, DXP pathway associated polypeptide (e.g., DXP partner proteins), isoprene

synthase polypeptide, and IDI polypeptide, or catalytically active fragment thereof) and may optionally include part or all of a second polypeptide (*e.g.*, a peptide that facilitates purification or detection of the fusion polypeptide, such as a His-tag). In some aspects, the fusion polypeptide has an activity of two or more DXP pathway polypeptides.

**[0042]** In particular aspects, the nucleic acid includes a segment of or the entire nucleic acid sequence of any iron-sulfur cluster-interacting redox nucleic acid, IspG nucleic acid, DXP pathway nucleic acid, DXP pathway associated nucleic acid (*e.g.*, DXP partner proteins), isoprene synthase nucleic acid, or IDI nucleic acid. In some aspects, the nucleic acid includes at least or about 50, 100, 150, 200, 300, 400, 500, 600, 700, 800, or more contiguous nucleotides from a iron-sulfur cluster-interacting redox nucleic acid, IspG, DXP pathway nucleic acid, DXP pathway associated nucleic acid, isoprene synthase nucleic acid, or IDI nucleic acid. In some aspects, the nucleic acid has one or more mutations compared to the sequence of a wild-type (*i.e.*, a sequence occurring in nature) IspG nucleic acid, iron-sulfur cluster-interacting redox nucleic acid, DXP pathway nucleic acid, DXP pathway associated nucleic acid, isoprene synthase nucleic acid, or IDI nucleic acid. In some aspects, the nucleic acid has one or more mutations (*e.g.*, a silent mutation) that increase the transcription or translation of IspG nucleic acid, iron-sulfur cluster-interacting redox nucleic acid, DXP pathway nucleic acid, DXP pathway associated nucleic acid, isoprene synthase nucleic acid, or IDI nucleic acid. In some aspects, the nucleic acid is a degenerate variant of any nucleic acid encoding an IspG polypeptide, iron-sulfur cluster-interacting redox polypeptide, DXP pathway polypeptide, DXP pathway associated polypeptide, isoprene synthase polypeptide, or IDI polypeptide.

**[0043]** The accession numbers of exemplary isoprene synthase and DXP pathway polypeptides and nucleic acids are listed in Appendix 1 of WO 2009/076676 and also further detailed herein.

#### *Exemplary Iron-sulfur Cluster-Interacting Redox Polypeptides and Nucleic Acids*

**[0044]** Iron-sulfur cluster-interacting redox polypeptide plays an essential role in the DXP pathway for isoprenoid biosynthesis. Exemplary iron-sulfur cluster-interacting redox polypeptides include polypeptides, fragments of polypeptides, peptides, and fusions

polypeptides that have at least one activity of a iron-sulfur cluster-interacting redox polypeptide. Standard methods can be used to determine whether a polypeptide has iron-sulfur cluster-interacting redox polypeptide activity by using a hydrogenase-linked assay measuring the rate of metronidazole[1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole] reduction (Chen and Blanchard, *Analytical Biochem*, 93:216-222 (1979)).

**[0045]** Exemplary iron-sulfur cluster-interacting redox polypeptide nucleic acids include nucleic acids that encode a polypeptide, fragment of a polypeptide, peptide, or fusion polypeptide that has at least one activity of an iron-sulfur cluster-interacting redox polypeptide. Exemplary iron-sulfur cluster-interacting redox polypeptides and nucleic acids include naturally-occurring polypeptides and nucleic acids from any of the source organisms described herein as well as mutant polypeptides and nucleic acids derived from any of the source organisms described herein.

**[0046]** Iron-sulfur cluster-interacting redox polypeptide is a polypeptide that is capable of transferring electrons to a polypeptide containing an iron-sulfur cluster. An iron-sulfur cluster-interacting redox polypeptide includes, but is not limited to, flavodoxin (*e.g.*, flavodoxin I), flavodoxin reductase, ferredoxin (*e.g.*, ferredoxin I), ferredoxin-NADP+ oxidoreductase, and genes or polypeptides encoding thereof (*e.g.*, *fpr* or *fldA*). For example, DXP pathway polypeptide HDS (GcpE) is a metallo-enzyme possessing a [4Fe-4S]<sup>2+</sup> center and catalyzes the reduction of cMEPP into HMBPP via two successive one-electron transfers mediated by the reduction of [4Fe-4S]<sup>2+</sup> center in the presence of flavodoxin/flavodoxin reductase (*see*, Wolff *et al.*, *FEBS Letters*, 541:115-120 (2003)). Similarly, DXP pathway polypeptide HDR (LytB) is also a Fe/S protein catalyzing the reduction of HMBPP into IPP or DMAPP via two successive one-electron transfers in the presence of flavodoxin/flavodoxin reductase/NADPH system. *See*, for example, Seemann, M. *et al.* *Agnew. Chem. Int. Ed.*, 41: 4337-4339 (2002); Wolff, M. *et al.*, *FEBS Letters*, 541: 115-120 (2003)).

**[0047]** Flavodoxin is a protein that is capable of transferring electrons and contains the prosthetic group flavin mononucleotide. In *Escherichia coli* (*E. coli*), flavodoxin is encoded by the *fldA* gene and reduced by the FAD-containing protein NADPH:ferredoxin

oxidoreductase, and plays an essential role in the DXP pathway for isoprenoid biosynthesis (see, example, Kia-Joo, P. *et al. FEBS Letters*, 579: 3802-3806, 2005).

**[0048]** Ferredoxin is a protein that is capable of transferring electron and contains iron and labile sulfur in equal amounts and plays an essential role in the DXP pathway for isoprenoid biosynthesis. For example, HDS from plants and cyanobacteria have been shown to be ferredoxin, rather than flavodoxin-dependent, enzymes (Seemann *et al.*, *FEBS Lett.*, 580(6):1547-52 (2006)).

**[0049]** *Fpr* encodes flavodoxin/ferredoxin NADPH-oxidoreductase and provides the necessary electron derived from NADPH via FldA for HDS and HDR to perform their catalytic functions (reviewed in report by L. A. Furgerson, *The Mevalonate-Independent Pathway to Isoprenoid Compounds: Discovery, Elucidation, and Reaction Mechanisms*, published February 13, 2006).

#### *Exemplary DXP Pathway Polypeptides and Nucleic Acids*

**[0050]** Exemplary DXP pathway polypeptides include, but are not limited to any of the following polypeptides: DXS polypeptides, DXR polypeptides, MCT polypeptides, CMK polypeptides, MCS polypeptides, HDS polypeptides, HDR polypeptides, IDI polypeptides, and polypeptides (*e.g.*, fusion polypeptides) having an activity of one, two, or more of the DXP pathway polypeptides. In particular, DXP pathway polypeptides include polypeptides, fragments of polypeptides, peptides, and fusions polypeptides that have at least one activity of a DXP pathway polypeptide. Exemplary DXP pathway nucleic acids include nucleic acids that encode a polypeptide, fragment of a polypeptide, peptide, or fusion polypeptide that has at least one activity of a DXP pathway polypeptide. Exemplary DXP pathway polypeptides and nucleic acids include naturally-occurring polypeptides and nucleic acids from any of the source organisms described herein as well as mutant polypeptides and nucleic acids derived from any of the source organisms described herein.

**[0051]** In particular, DXS polypeptides convert pyruvate and D-glyceraldehyde 3-phosphate into 1-deoxy-d-xylulose 5-phosphate (DXP). Standard methods can be used to determine whether a polypeptide has DXS polypeptide activity by measuring the ability of

the polypeptide to convert pyruvate and D-glyceraldehyde 3-phosphate *in vitro*, in a cell extract, or *in vivo*.

**[0052]** DXR polypeptides convert 1-deoxy-d-xylulose 5-phosphate (DXP) into 2-C-methyl-D-erythritol 4-phosphate (MEP). Standard methods can be used to determine whether a polypeptide has DXR polypeptides activity by measuring the ability of the polypeptide to convert DXP *in vitro*, in a cell extract, or *in vivo*.

**[0053]** MCT polypeptides convert 2-C-methyl-D-erythritol 4-phosphate (MEP) into 4-(cytidine 5'-diphospho)-2-methyl-D-erythritol (CDP-ME). Standard methods can be used to determine whether a polypeptide has MCT polypeptides activity by measuring the ability of the polypeptide to convert MEP *in vitro*, in a cell extract, or *in vivo*.

**[0054]** CMK polypeptides convert 4-(cytidine 5'-diphospho)-2-C-methyl-D-erythritol (CDP-ME) into 2-phospho-4-(cytidine 5'-diphospho)-2-C-methyl-D-erythritol (CDP-MEP). Standard methods can be used to determine whether a polypeptide has CMK polypeptides activity by measuring the ability of the polypeptide to convert CDP-ME *in vitro*, in a cell extract, or *in vivo*.

**[0055]** MCS polypeptides convert 2-phospho-4-(cytidine 5'-diphospho)-2-C-methyl-D-erythritol (CDP-MEP) into 2-C-methyl-D-erythritol 2, 4-cyclodiphosphate (ME-CPP or cMEPP). Standard methods can be used to determine whether a polypeptide has MCS polypeptides activity by measuring the ability of the polypeptide to convert CDP-MEP *in vitro*, in a cell extract, or *in vivo*.

**[0056]** HDS polypeptides convert 2-C-methyl-D-erythritol 2, 4-cyclodiphosphate into (E)-4-hydroxy-3-methylbut-2-en-1-yl diphosphate (HMBPP or HDMAPP). Standard methods can be used to determine whether a polypeptide has HDS polypeptides activity by measuring the ability of the polypeptide to convert ME-CPP *in vitro*, in a cell extract, or *in vivo*.

**[0057]** HDR polypeptides convert (E)-4-hydroxy-3-methylbut-2-en-1-yl diphosphate (HMBPP or HDMAPP) into isopentenyl diphosphate (IPP) and dimethylallyl diphosphate



(DMAPP). In one embodiment, the *ispH* gene can be used to encode for HDR polypeptides. IspH is also known as 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate reductase, 4Fe-4S protein, LytB, ECK0030, JW0027, *lytB*, *yaaE*, and *b0029*. Standard methods can be used to determine whether a polypeptide has HDR polypeptides activity by measuring the ability of the polypeptide to convert HMBPP *in vitro*, in a cell extract, or *in vivo*.

**[0058]** IDI polypeptides convert isopentenyl diphosphate into dimethylallyl diphosphate. Standard methods can be used to determine whether a polypeptide has IDI polypeptides activity by measuring the ability of the polypeptide to convert isopentenyl diphosphate *in vitro*, in a cell extract, or *in vivo*.

#### *Exemplary Polypeptides and nucleic acids associated with DXP Pathway*

**[0059]** Various polypeptides associated with DXP pathway (e.g., DXP partner proteins) and nucleic acids encoding for those polypeptides can be used in conjunction with any one or more of the isoprene synthase(s), DXP pathway polypeptide(s) and/or MVA pathway polypeptide(s). In one embodiment, chaperonins can be used. Chaperonins facilitate the folding and un-folding of proteins, an activity required for the competent tertiary structure to be attained. Chaperones of this class are involved in both generating and repairing the 3-D structure of proteins, working to achieve and maintain protein functionality. The *E. coli* chaperonins DnaK and GroEL/GroES are well characterized examples of such enzymes (Bukau *et al.*, *Cell*, 92:351-366 (1998)). Chaperonins facilitate the delivery, maintenance, and repair of cofactors required for enzyme catalysis. In one embodiment, such chaperonins can be those enzyme chaperones involved in the functionality of iron-sulfur cluster cofactors. The *iscR* operon genes *hrcA*, *hrcB*, and *iscA* as well as *erpA* and the additional A-type carrier proteins of *E. coli* are non-limiting examples of the class of chaperonins which can be used, serving among those involved in the delivery, maintenance, and repair of iron-sulfur clusters within *E. coli* (Tokumoto and Takahashi, *J. Biochem.*, 130: 63-71 (2001); Loiseau *et al.*, *PNAS*, 104(34): 13626-13631 (2007); Vinella *et al.*, *PLOS Genetics*, 5(5): 1-16 of e1000497 (2009)). In another embodiment, the *iscS* gene can be used. In addition to the better characterized role in *de novo* iron-sulfur cluster biogenesis, the *iscS* gene has been implicated in repair of damaged iron-sulfur clusters and can serve as an example of said chaperone (Djaman *et al.*, *J. Biol. Chem.*, 279(43): 44590-44599 (2004). Similarly, the Ric protein

encoded by *ytfE* and ferritin A encoded by *ftn* of *E. coli* are further examples of chaperonins involved in the repair of iron-sulfur clusters (Justino *et al.*, *Biometals*, 22: 99-108 (2009); Justino *et al.*, *J. Biol. Chem.*, 282(14): 10352-10359 (2007); Bitoun *et al.*, *Biometals*, 21: 693-703 (2008).

#### *Exemplary Isoprene Synthase Polypeptides and Nucleic Acids*

**[0060]** As noted above, isoprene synthase polypeptides convert dimethylallyl diphosphate (DMAPP) into isoprene. Exemplary isoprene synthase nucleic acids include nucleic acids that encode a polypeptide, fragment of a polypeptide, peptide, or fusion polypeptide that has at least one activity of an isoprene synthase polypeptide. Exemplary isoprene synthase polypeptides and nucleic acids include naturally-occurring polypeptides and nucleic acids from any of the source organisms described herein as well as mutant polypeptides and nucleic acids derived from any of the source organisms described herein.

**[0061]** In some aspects of the invention, the recombinant cells described in any of the compositions or methods described herein further comprise one or more nucleic acids encoding an isoprene synthase polypeptide or a polypeptide having isoprene synthase activity. In some aspects, the isoprene synthase polypeptide is an endogenous polypeptide. In some aspects, the endogenous nucleic acid encoding an isoprene synthase polypeptide is operably linked to a constitutive promoter. In some aspects, the endogenous nucleic acid encoding an isoprene synthase polypeptide is operably linked to an inducible promoter. In some aspects, the endogenous nucleic acid encoding an isoprene synthase polypeptide is operably linked to a strong promoter. In some aspects, more than one endogenous nucleic acid encoding an isoprene synthase polypeptide is used (e.g, 2, 3, 4, or more copies of an endogenous nucleic acid encoding an isoprene synthase polypeptide). In a particular aspect, the cells are engineered to overexpress the endogenous isoprene synthase pathway polypeptide relative to wild-type cells. In some aspects, the endogenous nucleic acid encoding an isoprene synthase polypeptide is operably linked to a weak promoter.

**[0062]** In some aspects, the isoprene synthase polypeptide is a heterologous polypeptide. In some aspects, the cells comprise more than one copy of a heterologous nucleic acid encoding an isoprene synthase polypeptide. In some aspects, the heterologous nucleic acid

encoding an isoprene synthase polypeptide is operably linked to a constitutive promoter. In some aspects, the heterologous nucleic acid encoding an isoprene synthase polypeptide is operably linked to an inducible promoter. In some aspects, the heterologous nucleic acid encoding an isoprene synthase polypeptide is operably linked to a strong promoter. In some aspects, the heterologous nucleic acid encoding an isoprene synthase polypeptide is operably linked to a weak promoter.

**[0063]** The nucleic acids encoding an isoprene synthase polypeptide(s) can be integrated into a genome of the host cells or can be stably expressed in the cells. The nucleic acids encoding an isoprene synthase polypeptide(s) can additionally be on a vector.

**[0064]** In some aspects, the isoprene synthase polypeptide or nucleic acid is from the family Fabaceae, such as the Faboideae subfamily. In some aspects, the isoprene synthase polypeptide is a polypeptide from *Pueraria* or *Populus* or a hybrid such as *Populus alba* x *Populus tremula*. In some aspects, the isoprene synthase polypeptide or nucleic acid is a polypeptide or nucleic acid from *Pueraria montana* (kudzu) (Sharkey *et al.*, Plant Physiology 137: 700-712, 2005), *Pueraria lobata*, poplar (such as *Populus alba*, *Populus nigra*, *Populus trichocarpa*, or *Populus alba* x *tremula* (CAC35696) Miller *et al.*, Planta 213: 483-487, 2001) aspen (such as *Populus tremuloides*) Silver *et al.*, JBC 270(22): 13010-1316, 1995), or English Oak (*Quercus robur*) (Zimmer *et al.*, WO 98/02550). Suitable isoprene synthases include, but are not limited to, those identified by Genbank Accession Nos. AY341431, AY316691, AY279379, AJ457070, and AY182241. In some aspects, the isoprene synthase polypeptide or nucleic acid is not a naturally-occurring polypeptide or nucleic acid from *Quercus robur* (*i.e.*, the isoprene synthase polypeptide or nucleic acid is an isoprene synthase polypeptide or nucleic acid other than a naturally-occurring polypeptide or nucleic acid from *Quercus robur*). In some aspects, the isoprene synthase nucleic acid or polypeptide is a naturally-occurring polypeptide or nucleic acid from poplar. In some aspects, the isoprene synthase nucleic acid or polypeptide is not a naturally-occurring polypeptide or nucleic acid from poplar.

**[0065]** In some aspects, the isoprene synthase nucleic acid or polypeptide is a naturally-occurring polypeptide or nucleic acid (*e.g.*, naturally-occurring polypeptide or nucleic acid from *Populus*). In some aspects, the isoprene synthase nucleic acid or polypeptide is not a

wild-type or naturally-occurring polypeptide or nucleic acid. In some aspects, the isoprene synthase nucleic acid or polypeptide is a variant of a wild-type or naturally-occurring polypeptide or nucleic acid (*e.g.*, a variant of a wild-type or naturally-occurring polypeptide or nucleic acid from *Populus*).

**[0066]** In some aspects, the isoprene synthase polypeptide is a variant. Variants of isoprene synthase can possess improved activity such as improved enzymatic activity. In some aspects, an isoprene synthase variant has other improved properties, such as improved stability (*e.g.*, thermo-stability), and/or improved solubility. In some aspects, the isoprene synthase polypeptide is a variant of a wild-type or naturally occurring isoprene synthase. In some aspects, the variant has improved activity such as improved catalytic activity compared to the wild-type or naturally occurring isoprene synthase. The increase in activity (*e.g.*, catalytic activity) can be at least about any of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%. In some aspects, the increase in activity such as catalytic activity is at least about any of 1 fold, 2 folds, 5 folds, 10 folds, 20 folds, 30 folds, 40 folds, 50 folds, 75 folds, or 100 folds. In some aspects, the increase in activity such as catalytic activity is about 10% to about 100 folds (*e.g.*, about 20% to about 100 folds, about 50% to about 50 folds, about 1 fold to about 25 folds, about 2 folds to about 20 folds, or about 5 folds to about 20 folds). In some aspects, the variant has improved solubility compared to the wild-type or naturally occurring isoprene synthase. The increase in solubility can be at least about any of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%. The increase in solubility can be at least about any of 1 fold, 2 folds, 5 folds, 10 folds, 20 folds, 30 folds, 40 folds, 50 folds, 75 folds, or 100 folds. In some aspects, the increase in solubility is about 10% to about 100 folds (*e.g.*, about 20% to about 100 folds, about 50% to about 50 folds, about 1 fold to about 25 folds, about 2 folds to about 20 folds, or about 5 folds to about 20 folds). In some aspects, the isoprene synthase polypeptide is a variant of naturally occurring isoprene synthase and has improved stability (such as thermo-stability) compared to the naturally occurring isoprene synthase.

**[0067]** In some aspects, the variant has at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 110%, at least about 120%, at least about 130%, at least about 140%, at least about 150%, at least about 160%, at

least about 170%, at least about 180%, at least about 190%, at least about 200% of the activity of a wild-type or naturally occurring isoprene synthase. The variant can share sequence similarity with a wild-type or naturally occurring isoprene synthase. In some aspects, a variant of a wild-type or naturally occurring isoprene synthase can have at least about any of 40%, 50%, 60%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% amino acid sequence identity as that of the wild-type or naturally occurring isoprene synthase. In some aspects, a variant of a wild-type or naturally occurring isoprene synthase has any of about 70% to about 99.9%, about 75% to about 99%, about 80% to about 98%, about 85% to about 97%, or about 90% to about 95% amino acid sequence identity as that of the wild-type or naturally occurring isoprene synthase.

**[0068]** In some aspects, the variant comprises a mutation in the wild-type or naturally occurring isoprene synthase. In some aspects, the variant has at least one amino acid substitution, at least one amino acid insertion, and/or at least one amino acid deletion. In some aspects, the variant has at least one amino acid substitution. In some aspects, the number of differing amino acid residues between the variant and wild-type or naturally occurring isoprene synthase can be one or more, *e.g.* 1, 2, 3, 4, 5, 10, 15, 20, 30, 40, 50, or more amino acid residues. Naturally occurring isoprene synthases can include any isoprene synthases from plants, for example, kudzu isoprene synthases, poplar isoprene synthases, English oak isoprene synthases, and willow isoprene synthases. In some aspects, the variant is a variant of isoprene synthase from *Populus alba*. In some aspects, the variant of isoprene synthase from *Populus alba* has at least one amino acid substitution, at least one amino acid insertion, and/or at least one amino acid deletion. In some aspects, the variant is a truncated *Populus alba* isoprene synthase. In some aspects, the nucleic acid encoding variant (*e.g.*, variant of isoprene synthase from *Populus alba*) is codon optimized (for example, codon optimized based on host cells where the heterologous isoprene synthase is expressed).

**[0069]** The isoprene synthase polypeptide provided herein can be any of the isoprene synthases or isoprene synthase variants described in WO 2009/132220, WO 2010/124146, U.S. Patent Application Publication No.: 2010/0086978, US Appl. 13/283,564 and PCT/US2011/058188, the contents of which are expressly incorporated herein by reference in their entirety with respect to the isoprene synthases and isoprene synthase variants. Suitable isoprene synthases include, but are not limited to, those identified by Genbank Accession

Nos. AY341431, AY316691, AY279379, AJ457070, and AY182241. Types of isoprene synthases which can be used in any one of the compositions or methods including methods of making microorganisms encoding isoprene synthase described herein are also described in International Patent Application Publication Nos. WO2009/076676, WO2010/003007, WO2009/132220, WO2010/031062, WO2010/031068, WO2010/031076, WO2010/013077, WO2010/031079, WO2010/148150, WO2010/124146, WO2010/078457, and WO2010/148256, the contents of which are expressly incorporated herein by reference in their entirety with respect to the isoprene synthases and isoprene synthase variants.

**[0070]** Any one of the promoters described herein (*e.g.*, promoters described herein and identified in the Examples of the present disclosure including inducible promoters and constitutive promoters) can be used to drive expression of any of the isoprene synthases described herein.

**[0071]** Standard methods can be used to determine whether a polypeptide has isoprene synthase polypeptide activity by measuring the ability of the polypeptide to convert DMAPP into isoprene *in vitro*, in a cell extract, or *in vivo*. In an exemplary assay, cell extracts are prepared by growing a strain (*e.g.*, the *E. coli*/pTrcKudzu strain described herein) in the shake flask method as described in Example 1. After induction is complete, approximately 10 mL of cells are pelleted by centrifugation at 7000 x g for 10 minutes and resuspended in 5 ml of PEB without glycerol. The cells are lysed using a French Pressure cell using standard procedures. Alternatively the cells are treated with lysozyme (Ready-Lyse lysozyme solution; EpiCentre) after a freeze/thaw at -80C.

**[0072]** Isoprene synthase polypeptide activity in the cell extract can be measured, for example, as described in Silver *et al.*, J. Biol. Chem. 270:13010-13016, 1995 and references therein, which are each hereby incorporated by reference in their entireties, particularly with respect to assays for isoprene synthase polypeptide activity. DMAPP (Sigma) is evaporated to dryness under a stream of nitrogen and rehydrated to a concentration of 100 mM in 100 mM potassium phosphate buffer pH 8.2 and stored at -20 0C. To perform the assay, a solution of 5 µL of 1M MgCl<sub>2</sub>, 1 mM (250 µg/ml) DMAPP, 65 µL of Plant Extract Buffer (PEB) (50 mM Tris-HCl, pH 8.0, 20 mM MgCl<sub>2</sub>, 5% glycerol, and 2 mM DTT) is added to 25 µL of cell extract in a 20 ml Headspace vial with a metal screw cap and teflon coated

silicon septum (Agilent Technologies) and cultured at 37 °C for 15 minutes with shaking. The reaction can be quenched by adding 200 µL of 250 mM EDTA and quantified by GC/MS.

*Exemplary MVA Pathway Polypeptides and Nucleic Acids*

**[0073]** In some aspects of the invention, the cells described in any of the compositions or methods described herein comprise a nucleic acid encoding an MVA pathway polypeptide. In some aspects, the MVA pathway polypeptide is an endogenous polypeptide. In some aspects, the cells comprise one or more additional copies of an endogenous nucleic acid encoding an MVA pathway polypeptide. In some aspects, the endogenous nucleic acid encoding an MVA pathway polypeptide operably linked to a constitutive promoter. In some aspects, the endogenous nucleic acid encoding an MVA pathway polypeptide operably linked to a constitutive promoter. In some aspects, the endogenous nucleic acid encoding an MVA pathway polypeptide is operably linked to a strong promoter. In a particular aspect, the cells are engineered to over-express the endogenous MVA pathway polypeptide relative to wild-type cells.

**[0074]** In some aspects, the MVA pathway polypeptide is a heterologous polypeptide. In some aspects, the cells comprise more than one copy of a heterologous nucleic acid encoding an MVA pathway polypeptide. In some aspects, the heterologous nucleic acid encoding an MVA pathway polypeptide is operably linked to a constitutive promoter. In some aspects, the heterologous nucleic acid encoding an MVA pathway polypeptide is operably linked to a strong promoter.

**[0075]** Exemplary MVA pathway polypeptides include acetyl-CoA acetyltransferase (AA-CoA thiolase) polypeptides, acetoacetyl-CoA synthase (which utilizes acetyl-CoA and malonyl-CoA), 3-hydroxy-3-methylglutaryl-CoA synthase (HMG-CoA synthase) polypeptides, 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase) polypeptides, mevalonate kinase (MVK) polypeptides, phosphomevalonate kinase (PMK) polypeptides, diphosphomevalonate decarboxylase (MVD) polypeptides, phosphomevalonate decarboxylase (PMDC) polypeptides, isopentenyl phosphate kinase (IPK) polypeptides, IDI polypeptides, and polypeptides (*e.g.*, fusion polypeptides) having an activity of two or more

MVA pathway polypeptides. In particular, MVA pathway polypeptides include polypeptides, fragments of polypeptides, peptides, and fusions polypeptides that have at least one activity of an MVA pathway polypeptide. Exemplary MVA pathway nucleic acids include nucleic acids that encode a polypeptide, fragment of a polypeptide, peptide, or fusion polypeptide that has at least one activity of an MVA pathway polypeptide. Exemplary MVA pathway polypeptides and nucleic acids include naturally-occurring polypeptides and nucleic acids from any of the source organisms described herein. In addition, variants of MVA pathway polypeptide that confer the result of better isoprene production can also be used as well.

[0076] In certain aspects, the one or more nucleic acids encoding one or more MVA pathway polypeptides is a heterologous nucleic acid. In other aspects, the one or more nucleic acids encoding one or more MVA pathway polypeptides is a copy of an endogenous nucleic acid. In any of the aspects herein, one or more MVA pathway polypeptides can be selected from (a) an enzyme that condenses two molecules of acetyl-CoA to form acetoacetyl-CoA (AA-CoA thiolase) or an enzyme that can synthesize acetoacetyl-CoA from malonyl-CoA and acetyl-CoA (acetoacetyl-CoA synthase); (b) an enzyme that condenses acetoacetyl-CoA with acetyl-CoA to form HMG-CoA (e.g., HMG synthase); (c) an enzyme that converts HMG-CoA to mevalonate; (d) an enzyme that phosphorylates mevalonate to mevalonate 5-phosphate; (e) an enzyme that converts mevalonate 5-phosphate to mevalonate 5-pyrophosphate; (f) an enzyme that converts mevalonate 5-pyrophosphate to isopentenyl pyrophosphate; and (g) an enzyme that converts isopentenyl pyrophosphate to dimethylallyl diphosphate. In any of the aspects herein, one or more MVA pathway polypeptides is selected from (a) an enzyme that condenses acetoacetyl-CoA with acetyl-CoA to form HMG-CoA (e.g., HMG synthase); (b) an enzyme that converts HMG-CoA to mevalonate; (c) an enzyme that phosphorylates mevalonate to mevalonate 5-phosphate; (d) an enzyme that converts mevalonate 5-phosphate to mevalonate 5-pyrophosphate; and (e) an enzyme that converts mevalonate 5-pyrophosphate to isopentenyl pyrophosphate.

[0077] Types of MVA pathway polypeptides and/or DXP pathway polypeptides which can be used and methods of making microorganisms encoding MVA pathway polypeptides and/or DXP pathway polypeptides are also described in International Patent Application Publication No. WO2009/076676.



[0078] One of skill in the art can readily select and/or use suitable promoters to optimize the expression of isoprene synthase or and one or more MVA pathway polypeptides and/or one or more DXP pathway polypeptides. Similarly, one of skill in the art can readily select and/or use suitable vectors (or transfer vehicle) to optimize the expression of isoprene synthase or and one or more MVA pathway polypeptides and/or one or more DXP pathway polypeptides. In some aspects, the vector contains a selective marker. Examples of selectable markers include, but are not limited to, antibiotic resistance nucleic acids (*e.g.*, kanamycin, ampicillin, carbenicillin, gentamicin, hygromycin, phleomycin, bleomycin, neomycin, or chloramphenicol) and/or nucleic acids that confer a metabolic advantage, such as a nutritional advantage on the host cell. In some aspects, an isoprene synthase or MVA pathway nucleic acid integrates into a chromosome of the cells without a selective marker.

#### *Exemplary Source Organisms*

[0079] Iron-sulfur cluster-interacting redox nucleic acid, DXP pathway nucleic acid, DXP pathway associated nucleic acid, isoprene synthase nucleic acid, or IDI nucleic acid (and their encoded polypeptides) can be obtained from any organism that naturally includes iron-sulfur cluster-interacting redox nucleic acid, DXP pathway nucleic acid, DXP pathway associated nucleic acid, isoprene synthase nucleic acid, and/or IDI nucleic acid. As noted above, isoprene is formed naturally by a variety of organisms, such as bacteria, yeast, plants, and animals. Organisms include the MVA pathway, DXP pathway, or both the MVA and DXP pathways for producing isoprene (Figure 3). Thus, DXS, DXR, MCT, CMK, MCS, HDS, or HDR nucleic acids can be obtained, *e.g.*, from any organism that has the DXP pathway or has both the MVA and DXP pathways. IDI and isoprene synthase nucleic acids can be obtained, *e.g.*, from any organism that contains the MVA pathway, DXP pathway, or both the MVA and DXP pathways.

[0080] In some aspects, the nucleic acid sequence of the iron-sulfur cluster-interacting redox nucleic acid, DXP pathway nucleic acid, DXP pathway associated nucleic acid, isoprene synthase nucleic acid, or IDI nucleic acid is identical to the sequence of a nucleic acid that is produced by any of the following organisms in nature. In some aspects, the amino acid sequence of iron-sulfur cluster-interacting redox polypeptide, DXP pathway polypeptide, DXP pathway associated polypeptide, isoprene synthase polypeptide, or IDI polypeptide is identical to the sequence of a polypeptide that is produced by any of the

following organisms in nature. In some aspects, the iron-sulfur cluster-interacting redox nucleic acid, DXP pathway nucleic acid, DXP pathway associated nucleic acid, isoprene synthase nucleic acid, or IDI nucleic acid or its encoded polypeptide is a mutant nucleic acid or polypeptide derived from any of the organisms described herein. As used herein, “derived from” refers to the source of the nucleic acid or polypeptide into which one or more mutations is introduced. For example, a polypeptide that is “derived from a plant polypeptide” refers to polypeptide of interest that results from introducing one or more mutations into the sequence of a wild-type (*i.e.*, a sequence occurring in nature) plant polypeptide.

[0081] In some aspects, the source organism is a fungus, examples of which are species of *Aspergillus* such as *A. oryzae* and *A. niger*, species of *Saccharomyces* such as *S. cerevisiae*, species of *Schizosaccharomyces* such as *S. pombe*, and species of *Trichoderma* such as *T. reesei*. In some aspects, the source organism is a filamentous fungal cell. The term “filamentous fungi” refers to all filamentous forms of the subdivision Eumycotina (*see*, Alexopoulos, C. J. (1962), *Introductory Mycology*, Wiley, New York). These fungi are characterized by a vegetative mycelium with a cell wall composed of chitin, cellulose, and other complex polysaccharides. The filamentous fungi are morphologically, physiologically, and genetically distinct from yeasts. Vegetative growth by filamentous fungi is by hyphal elongation and carbon catabolism is obligatory aerobic. The filamentous fungal parent cell may be a cell of a species of, but not limited to, *Trichoderma*, (*e.g.*, *Trichoderma reesei*, the asexual morph of *Hypocrea jecorina*, previously classified as *T. longibrachiatum*, *Trichoderma viride*, *Trichoderma koningii*, *Trichoderma harzianum*) (Sheir-Neirs *et al.*, *Appl. Microbiol. Biotechnol* 20: 46-53, 1984; ATCC No. 56765 and ATCC No. 26921); *Penicillium sp.*, *Humicola sp.* (*e.g.*, *H. insolens*, *H. lanuginosa*, or *H. grisea*); *Chrysosporium sp.* (*e.g.*, *C. lucknowense*), *Gliocladium sp.*, *Aspergillus sp.* (*e.g.*, *A. oryzae*, *A. niger*, *A. sojae*, *A. japonicus*, *A. nidulans*, or *A. awamori*) (Ward *et al.*, *Appl. Microbiol. Biotechnol.* 39: 7380743, 1993 and Goedegebuur *et al.*, *Genet* 41: 89-98, 2002), *Fusarium sp.*, (*e.g.*, *F. roseum*, *F. gramineum*, *F. cerealis*, *F. oxysporum*, or *F. venenatum*), *Neurospora sp.*, (*e.g.*, *N. crassa*), *Hypocrea sp.*, *Mucor sp.*, (*e.g.*, *M. miehei*), *Rhizopus sp.* and *Emericella sp.* (*see also*, Innis *et al.*, *Sci.* 228: 21-26, 1985). The term “*Trichoderma*” or “*Trichoderma sp.*” or “*Trichoderma spp.*” refer to any fungal genus previously or currently classified as *Trichoderma*.

[0082] In some aspects, the fungus is *A. nidulans*, *A. awamori*, *A. oryzae*, *A. aculeatus*, *A. niger*, *A. japonicus*, *T. reesei*, *T. viride*, *F. oxysporum*, or *F. solani*. Aspergillus strains are disclosed in Ward et al., Appl. Microbiol. Biotechnol. 39:738-743, 1993 and Goedegebuur et al., Curr Gene 41:89-98, 2002, which are each hereby incorporated by reference in their entireties, particularly with respect to fungi. In particular aspects, the fungus is a strain of Trichoderma, such as a strain of *T. reesei*. Strains of *T. reesei* are known and non-limiting examples include ATCC No. 13631, ATCC No. 26921, ATCC No. 56764, ATCC No. 56765, ATCC No. 56767, and NRRL 15709, which are each hereby incorporated by reference in their entireties, particularly with respect to strains of *T. reesei*. In some aspects, the host strain is a derivative of RL-P37. RL-P37 is disclosed in Sheir-Neiss *et al.*, Appl. Microbiol. Biotechnology 20:46–53, 1984.

[0083] In some aspects, the source organism is a yeast, such as *Saccharomyces sp.*, *Schizosaccharomyces sp.*, *Pichia sp.*, or *Candida sp.*

[0084] In some aspects, the source organism is a bacterium, such as strains of *Bacillus* such as *B. licheniformis* or *B. subtilis*, strains of *Pantoea* such as *P. citrea*, strains of *Pseudomonas* such as *P. alcaligenes*, strains of *Streptomyces* such as *S. lividans* or *S. rubiginosus*, strains of *Thermosynechococcus* such as *T. elongatus*, strains of *Sinorhizobium* such as *S. meliloti*, strains of *Helicobacter* such as *H. pylori*, strains of *Agrobacterium* such as *A. tumefaciens*, strains of *Deinococcus* such as *D. radiodurans*, strains of *Listeria* such as *L. monocytogenes*, strains of *Lactobacillus* such as *L. spp.*, or strains of *Escherichia* such as *E. coli*.

[0085] As used herein, “the genus *Bacillus*” includes all species within the genus “*Bacillus*,” as known to those of skill in the art, including but not limited to *B. subtilis*, *B. licheniformis*, *B. lentus*, *B. brevis*, *B. stearothermophilus*, *B. alkalophilus*, *B. amyloliquefaciens*, *B. clausii*, *B. halodurans*, *B. megaterium*, *B. coagulans*, *B. circulans*, *B. lautus*, and *B. thuringiensis*. It is recognized that the genus *Bacillus* continues to undergo taxonomical reorganization. Thus, it is intended that the genus include species that have been reclassified, including but not limited to such organisms as *B. stearothermophilus*, which is now named “*Geobacillus stearothermophilus*.” The production of resistant endospores in the presence of oxygen is considered the defining feature of the genus *Bacillus*, although this

characteristic also applies to the recently named *Alicyclobacillus*, *Amphibacillus*, *Aneurinibacillus*, *Anoxybacillus*, *Brevibacillus*, *Filobacillus*, *Gracilibacillus*, *Halobacillus*, *Paenibacillus*, *Salibacillus*, *Thermobacillus*, *Ureibacillus*, and *Virgibacillus*.

[0086] In some aspects, the source organism is a gram-positive bacterium. Non-limiting examples include strains of *Streptomyces* (e.g., *S. lividans*, *S. coelicolor*, or *S. griseus*), *Bacillus*, *Listeria* (e.g., *L. monocytogenes*) or *Lactobacillus* (e.g., *L. spp*). In some aspects, the source organism is a gram-negative bacterium, such as *E. coli*, *Pseudomonas sp*, or *H. pylori*.

[0087] In some aspects, the source organism is a plant, such as a plant from the family *Fabaceae*, such as the *Faboideae* subfamily. In some aspects, the source organism is *kudzu*, *poplar* (such as *Populus alba x tremula* CAC35696), *aspen* (such as *Populus tremuloides*), *Quercus robur*, *Arabidopsis* (such as *A. thaliana*), or *Zea* (such as *Z. mays*).

[0088] In some aspects, the source organism is an algae, such as a green algae, red algae, glaucophytes, chlorarachniophytes, euglenids, chromista, or dinoflagellates.

[0089] In some aspects, the source organism is a cyanobacterium, such as a cyanobacterium classified into any of the following groups based on morphology: *Chroococcales*, *Pleurocapsales*, *Oscillatoriales*, *Nostocales*, or *Stigonematales*. In some aspects, the cyanobacterium is *Thermosynechococcus elongates*.

#### *Exemplary Host Cells*

[0090] A variety of host cells can be used to express iron-sulfur cluster-interacting redox polypeptide, DXP pathway polypeptide, DXP pathway associated polypeptide, MVA pathway polypeptide, MVA pathway associated polypeptide, isoprene synthase polypeptide, or IDI polypeptide and to produce isoprene in the methods of the claimed invention. Exemplary host cells include cells from any of the organisms listed in the prior section under the heading “*Exemplary Source Organisms*.” The host cell may be a cell that naturally produces isoprene or a cell that does not naturally produce isoprene. In some aspects, the host cell naturally produces isoprene using the DXP pathway and an isoprene synthase, and

one or more DXP pathway polypeptide and iron-sulfur cluster-interacting redox polypeptides are added to enhance production of isoprene using this pathway. In some aspects, the host cell naturally produces isoprene using the DXP pathway and isoprene synthase, and one or more DXP pathway nucleic acids, one or more iron-sulfur cluster-interacting redox nucleic acids, and IDI are added to enhance production of isoprene using this pathway.

[0091] Thus, one of skill in the art will recognize that expression vectors can be designed to contain certain components which optimize gene expression for certain host strains. Such optimization components include, but are not limited to origin of replication, promoters, and enhancers. The vectors and components referenced herein are described for exemplary purposes and are not meant to narrow the scope of the invention.

[0092] Any cell or progeny thereof that can be used to heterologously express genes can be used herein to express iron-sulfur cluster-interacting redox polypeptide, DXP pathway polypeptide, DXP pathway associated polypeptide, MVA pathway polypeptide, MVA pathway associated polypeptide, isoprene synthase polypeptide, or IDI polypeptide and to produce isoprene in the methods of the claimed invention. In some embodiments, the host cell is a gram-positive bacterium. Non-limiting examples include strains of *Streptomyces* (e.g., *S. lividans*, *S. coelicolor*, or *S. griseus*), *Bacillus*, *Listeria* (e.g., *L. monocytogenes*) or *Lactobacillus* (e.g., *L. spp*). In some embodiments, the source organism is a gram-negative bacterium, such as *E. coli*, *Pseudomonas sp.*, or *H. pylori*. In certain embodiments, *E. coli* host cells can be used to express one or more iron-sulfur cluster-interacting redox polypeptide, DXP pathway polypeptide, DXP pathway associated polypeptide, MVA pathway polypeptide, MVA pathway associated polypeptide, isoprene synthase polypeptide, or IDI polypeptide and to produce isoprene in the methods of the claimed invention.

[0093] Bacteria cells, including gram positive or gram negative bacteria can be used to express any of the heterologous genes described above. In particular, any one of *P. citrea*, *B. subtilis*, *B. licheniformis*, *B. lentus*, *B. brevis*, *B. stearothermophilus*, *B. alkalophilus*, *B. amyloliquefaciens*, *B. clausii*, *B. halodurans*, *B. megaterium*, *B. coagulans*, *B. circulans*, *B. lautus*, *B. thuringiensis*, *S. albus*, *S. lividans*, *S. coelicolor*, *S. griseus*, *Pseudomonas sp.*, and *P. alcaligenes* cells.

[0094] There are numerous types of anaerobic cells that can be used as host cells in the compositions and methods of the present invention. In one aspect of the invention, the cells described in any of the compositions or methods described herein are obligate anaerobic cells and progeny thereof. Obligate anaerobes typically do not grow well, if at all, in conditions where oxygen is present. It is to be understood that a small amount of oxygen may be present, that is, there is some tolerance level that obligate anaerobes have for a low level of oxygen. In one aspect, obligate anaerobes engineered to produce mevalonate, isoprenoid precursors, isoprene, and isoprenoids can serve as host cells for any of the methods and/or compositions described herein and are grown under substantially oxygen-free conditions, wherein the amount of oxygen present is not harmful to the growth, maintenance, and/or fermentation of the anaerobes.

[0095] In another aspect of the invention, the host cells described and/or used in any of the compositions or methods described herein are facultative anaerobic cells and progeny thereof. Facultative anaerobes can generate cellular ATP by aerobic respiration (e.g., utilization of the TCA cycle) if oxygen is present. However, facultative anaerobes can also grow in the absence of oxygen. This is in contrast to obligate anaerobes which die or grow poorly in the presence of greater amounts of oxygen. In one aspect, therefore, facultative anaerobes can serve as host cells for any of the compositions and/or methods provided herein and can be engineered to produce mevalonate, isoprenoid precursors, isoprene, and isoprenoids. Facultative anaerobic host cells can be grown under substantially oxygen-free conditions, wherein the amount of oxygen present is not harmful to the growth, maintenance, and/or fermentation of the anaerobes, or can be alternatively grown in the presence of greater amounts of oxygen.

[0096] The host cell can additionally be a filamentous fungal cell and progeny thereof. (See, e.g., Berka & Barnett, *Biotechnology Advances*, (1989), 7(2):127-154). In some aspects, the filamentous fungal cell can be any of *Trichoderma longibrachiatum*, *T. viride*, *T. koningii*, *T. harzianum*, *Penicillium sp.*, *Humicola insolens*, *H. lanuginosa*, *H. grisea*, *Chrysosporium sp.*, *C. lucknowense*, *Gliocladium sp.*, *Aspergillus sp.*, such as *A. oryzae*, *A. niger*, *A. sojae*, *A. japonicus*, *A. nidulans*, or *A. awamori*, *Fusarium sp.*, such as *F. roseum*, *F. gramineum*, *F. cerealis*, *F. oxysporum*, or *F. venenatum*, *Neurospora sp.*, such as *N. crassa*, *Hypocrea sp.*, *Mucor sp.*, such as *M. miehei*, *Rhizopus sp.* or *Emericella sp.* In some aspects,

the fungus is *A. nidulans*, *A. awamori*, *A. oryzae*, *A. aculeatus*, *A. niger*, *A. japonicus*, *T. reesei*, *T. viride*, *F. oxysporum*, or *F. solani*. In certain embodiments, plasmids or plasmid components for use herein include those described in U.S. patent pub. No. US 2011/0045563.

[0097] The host cell can also be a yeast, such as *Saccharomyces sp.*, *Schizosaccharomyces sp.*, *Pichia sp.*, or *Candida sp.* In some aspects, the *Saccharomyces sp.* is *Saccharomyces cerevisiae* (See, e.g., Romanos et al., *Yeast*, (1992), 8(6):423-488). In certain embodiments, plasmids or plasmid components for use herein include those described in U.S. pat. No. 7,659,097 and U.S. patent pub. No. US 2011/0045563.

[0098] The host cell can additionally be a species of algae, such as a green algae, red algae, glaucophytes, chlorarachniophytes, euglenids, chromista, or dinoflagellates. (See, e.g., Saunders & Warmbrodt, "*Gene Expression in Algae and Fungi, Including Yeast*," (1993), National Agricultural Library, Beltsville, MD). In certain embodiments, plasmids or plasmid components for use herein include those described in U.S. Patent Pub. No. US 2011/0045563. In some aspects, the host cell is a cyanobacterium, such as cyanobacterium classified into any of the following groups based on morphology: *Chlorococcales*, *Pleurocapsales*, *Oscillatoriales*, *Nostocales*, or *Stigonematales* (See, e.g., Lindberg et al., *Metab. Eng.*, (2010) 12(1):70-79). In certain embodiments, plasmids or plasmid components for use herein include those described in U.S. patent pub. No. US 2010/0297749; US 2009/0282545 and Intl. Pat. Appl. No. WO 2011/034863.

#### *Exemplary Transformation Methods*

[0099] IspG nucleic acids, iron-sulfur cluster-interacting redox nucleic acid, DXP pathway nucleic acid, DXP pathway associated nucleic acid, isoprene synthase nucleic acid, or IDI nucleic acid or its vectors comprising them can be inserted into a host cell (e.g., *E. coli* cell, an algal cell, a plant cell, a fungal cell, a yeast cell, or a bacterial cell described herein) using standard techniques known to one of skill in the art. The introduced nucleic acids may be integrated into chromosomal DNA or maintained as extrachromosomal replicating sequences.

#### *Additional Host cell Mutations*

[0100] In certain embodiments in which the recombinant cells described herein further comprise one or more one or more MVA pathway polypeptides, the invention further contemplates certain host cell mutations that increase carbon flux through the MVA pathway. In another embodiment, the invention contemplates certain host cell mutations that increase carbon flux through the DXP pathway. In another embodiment, the invention contemplates certain host cell mutations that increase carbon flux through the DXP and MVA pathways. By increasing the carbon flow, more isoprene can be produced. In certain embodiments, the recombinant cells as described herein can also be engineered for increased carbon flux towards mevalonate production wherein the activity of one or more enzymes from the group consisting of: (a) citrate synthase, (b) phosphotransacetylase; (c) acetate kinase; (d) lactate dehydrogenase; (e) NADP-dependent malic enzyme, and; (f) pyruvate dehydrogenase is modulated.

#### Citrate Synthase Pathway

[0101] Citrate synthase catalyzes the condensation of oxaloacetate and acetyl-CoA to form citrate, a metabolite of the Tricarboxylic acid (TCA) cycle (Ner, S. et al. 1983. *Biochemistry* 22: 5243-5249; Bhayana, V. and Duckworth, H. 1984. *Biochemistry* 23: 2900-2905) (Figure 5). In *E. coli*, this enzyme, encoded by *gltA*, behaves like a trimer of dimeric subunits. The hexameric form allows the enzyme to be allosterically regulated by NADH. This enzyme has been widely studied (Wiegand, G., and Remington, S. 1986. *Annual Rev. Biophysics Biophys. Chem.* 15: 97-117; Duckworth et al. 1987. *Biochem Soc Symp.* 54:83-92; Stockell, D. et al. 2003. *J. Biol. Chem.* 278: 35435-43; Maurus, R. et al. 2003. *Biochemistry.* 42:5555-5565). To avoid allosteric inhibition by NADH, replacement by or supplementation with the *Bacillus subtilis* NADH-insensitive citrate synthase has been considered (Underwood et al. 2002. *Appl. Environ. Microbiol.* 68:1071-1081; Sanchez et al. 2005. *Met. Eng.* 7:229-239).

[0102] The reaction catalyzed by citrate synthase is directly competing with the thiolase catalyzing the first step of the mevalonate pathway, as they both have acetyl-CoA as a substrate (Hedl et al. 2002. *J. Bact.* 184:2116-2122). Therefore, one of skill in the art can modulate citrate synthase expression (e.g., decrease enzyme activity) to allow more carbon to flux into the mevalonate pathway, thereby increasing the eventual production of mevalonate



and isoprene. Decrease of citrate synthase activity can be any amount of reduction of specific activity or total activity as compared to when no manipulation has been effectuated. In some instances, the decrease of enzyme activity is decreased by at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%. In some aspects, the activity of citrate synthase is modulated by decreasing the activity of an endogenous citrate synthase gene. This can be accomplished by chromosomal replacement of an endogenous citrate synthase gene with a transgene encoding an NADH-insensitive citrate synthase or by using a transgene encoding an NADH-insensitive citrate synthase that is derived from *Bacillus subtilis*. The activity of citrate synthase can also be modulated (e.g., decreased) by replacing the endogenous citrate synthase gene promoter with a synthetic constitutively low expressing promoter. The decrease of the activity of citrate synthase can result in more carbon flux into the mevalonate dependent biosynthetic pathway in comparison to microorganisms that do not have decreased expression of citrate synthase.

#### Pathways involving Phosphotransacetylase and/or Acetate Kinase

[0103] Phosphotransacetylase (*pta*) (Shimizu et al. 1969. Biochim. Biophys. Acta 191: 550-558) catalyzes the reversible conversion between acetyl-CoA and acetylphosphate (acetyl-P), while acetate kinase (*ackA*) (Kakuda, H. et al. 1994. J. Biochem. 11:916-922) uses acetyl-P to form acetate. These genes can be transcribed as an operon in *E. coli*. Together, they catalyze the dissimilation of acetate, with the release of ATP. Thus, one of skill in the art can increase the amount of available acetyl Co-A by attenuating the activity of phosphotransacetylase gene (e.g., the endogenous phosphotransacetylase gene) and/or an acetate kinase gene (e.g., the endogenous acetate kinase gene). One way of achieving attenuation is by deleting phosphotransacetylase (*pta*) and/or acetate kinase (*ackA*). This can be accomplished by replacing one or both genes with a chloramphenicol cassette followed by looping out of the cassette. Acetate is produced by *E. coli* for a variety of reasons (Wolfe, A. 2005. Microb. Mol. Biol. Rev. 69:12-50). Without being bound by theory, since *ackA-pta* use acetyl-CoA, deleting those genes might allow carbon not to be diverted into acetate and to increase the yield of mevalonate or isoprene.

[0104] In some aspects, the recombinant microorganism produces decreased amounts of acetate in comparison to microorganisms that do not have attenuated endogenous phosphotransacetylase gene and/or endogenous acetate kinase gene expression. Decrease in the amount of acetate produced can be measured by routine assays known to one of skill in the art. The amount of acetate reduction is at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% as compared when no molecular manipulations are done.

[0105] The activity of phosphotransacetylase (pta) and/or acetate kinase (ackA) can also be decreased by other molecular manipulation of the enzymes. The decrease of enzyme activity can be any amount of reduction of specific activity or total activity as compared to when no manipulation has been effectuated. In some instances, the decrease of enzyme activity is decreased by at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%.

[0106] In some cases, attenuating the activity of the endogenous phosphotransacetylase gene and/or the endogenous acetate kinase gene results in more carbon flux into the mevalonate dependent biosynthetic pathway in comparison to microorganisms that do not have attenuated endogenous phosphotransacetylase gene and/or endogenous acetate kinase gene expression.

#### Pathways Involving Lactate Dehydrogenase

[0107] In *E. coli*, D-Lactate is produced from pyruvate through the enzyme lactate dehydrogenase (ldhA – Figure 5) (Bunch, P. et al. 1997. Microbiol. 143:187-195). Production of lactate is accompanied with oxidation of NADH, hence lactate is produced when oxygen is limited and cannot accommodate all the reducing equivalents. Thus, production of lactate could be a source for carbon consumption. As such, to improve carbon flow through to mevalonate production (and isoprene), one of skill in the art can modulate the activity of lactate dehydrogenase, such as by decreasing the activity of the enzyme.

[0108] Accordingly, in one aspect, the activity of lactate dehydrogenase can be modulated by attenuating the activity of an endogenous lactate dehydrogenase gene. Such attenuation can be achieved by deletion of the endogenous lactate dehydrogenase gene. Other ways of attenuating the activity of lactate dehydrogenase gene known to one of skill in the art may also be used. By manipulating the pathway that involves lactate dehydrogenase, the recombinant microorganism produces decreased amounts of lactate in comparison to microorganisms that do not have attenuated endogenous lactate dehydrogenase gene expression. Decrease in the amount of lactate produced can be measured by routine assays known to one of skill in the art. The amount of lactate reduction is at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% as compared when no molecular manipulations are done.

[0109] The activity of lactate dehydrogenase can also be decreased by other molecular manipulations of the enzyme. The decrease of enzyme activity can be any amount of reduction of specific activity or total activity as compared to when no manipulation has been effectuated. In some instances, the decrease of enzyme activity is decreased by at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%.

[0110] Accordingly, in some cases, attenuation of the activity of the endogenous lactate dehydrogenase gene results in more carbon flux into the mevalonate dependent biosynthetic pathway in comparison to microorganisms that do not have attenuated endogenous lactate dehydrogenase gene expression.

#### Pathways Involving Malic enzyme

[0111] Malic enzyme (in *E. coli* *sfcA* and *maeB*) is an anaplerotic enzyme that catalyzes the conversion of malate into pyruvate (using NAD<sup>+</sup> or NADP<sup>+</sup>) by the equation below:

[0112] (S)-malate + NAD(P)<sup>+</sup>  $\rightleftharpoons$  pyruvate + CO<sub>2</sub> + NAD(P)H

[0113] Thus, the two substrates of this enzyme are (S)-malate and NAD(P)<sup>+</sup>, whereas its 3 products are pyruvate, CO<sub>2</sub>, and NADPH.

[0114] Expression of the NADP-dependent malic enzyme (maeB – Figure 5) (Iwikura, M. et al. 1979. *J. Biochem.* 85: 1355-1365) can help increase mevalonate and isoprene yield by 1) bringing carbon from the TCA cycle back to pyruvate, direct precursor of acetyl-CoA, itself direct precursor of the mevalonate pathway and 2) producing extra NADPH which could be used in the HMG-CoA reductase reaction (Oh, MK et al. (2002) *J. Biol. Chem.* 277: 13175-13183; Bologna, F. et al. (2007) *J Bact.* 189:5937-5946).

[0115] As such, more starting substrate (pyruvate or acetyl-CoA) for the downstream production of mevalonate or isoprene can be achieved by modulating, such as increasing, the activity and/or expression of malic enzyme. The NADP-dependent malic enzyme gene can be an endogenous gene. One non-limiting way to accomplish this is by replacing the endogenous NADP-dependent malic enzyme gene promoter with a synthetic constitutively expressing promoter. Another non-limiting way to increase enzyme activity is by using one or more heterologous nucleic acids encoding an NADP-dependent malic enzyme polypeptide. One of skill in the art can monitor the expression of maeB RNA during fermentation or culturing using readily available molecular biology techniques.

[0116] Accordingly, in some embodiments, the recombinant microorganism produces increased amounts of pyruvate in comparison to microorganisms that do not have increased expression of an NADP-dependent malic enzyme gene. In some aspects, increasing the activity of an NADP-dependent malic enzyme gene results in more carbon flux into the mevalonate dependent biosynthetic pathway in comparison to microorganisms that do not have increased NADP-dependent malic enzyme gene expression.

[0117] Increase in the amount of pyruvate produced can be measured by routine assays known to one of skill in the art. The amount of pyruvate increase can be at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% as compared when no molecular manipulations are done.

[0118] The activity of malic enzyme can also be increased by other molecular manipulations of the enzyme. The increase of enzyme activity can be any amount of increase of specific activity or total activity as compared to when no manipulation has been effectuated. In some instances, the increase of enzyme activity is at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%.

#### Pathways Involving Pyruvate Dehydrogenase Complex

[0119] The pyruvate dehydrogenase complex, which catalyzes the decarboxylation of pyruvate into acetyl-CoA, is composed of the proteins encoded by the genes *aceE*, *aceF* and *lpdA*. Transcription of those genes is regulated by several regulators. Thus, one of skill in the art can increase acetyl-CoA by modulating the activity of the pyruvate dehydrogenase complex. Modulation can be to increase the activity and/or expression (e.g., constant expression) of the pyruvate dehydrogenase complex. This can be accomplished by different ways, for example, by placing a strong constitutive promoter, like PL.6 (aattcatataaaaaacatacagataaccatctgcggtgataaattatctctgcggtgttgacataaataccactggcggtgatactgagcacatcagcaggacgcactgaccacatgaaggtg - lambda promoter, GenBank NC\_001416), in front of the operon or using one or more synthetic constitutively expressing promoters.

[0120] Accordingly, in one aspect, the activity of pyruvate dehydrogenase is modulated by increasing the activity of one or more genes of the pyruvate dehydrogenase complex consisting of (a) pyruvate dehydrogenase (E1), (b) dihydrolipoyl transacetylase, and (c) dihydrolipoyl dehydrogenase. It is understood that any one, two or three of these genes can be manipulated for increasing activity of pyruvate dehydrogenase. In another aspect, the activity of the pyruvate dehydrogenase complex can be modulated by attenuating the activity of an endogenous pyruvate dehydrogenase complex repressor gene, further detailed below. The activity of an endogenous pyruvate dehydrogenase complex repressor can be attenuated by deletion of the endogenous pyruvate dehydrogenase complex repressor gene.

[0121] In some cases, one or more genes of the pyruvate dehydrogenase complex are endogenous genes. Another way to increase the activity of the pyruvate dehydrogenase complex is by introducing into the microorganism one or more heterologous nucleic acids

encoding one or more polypeptides from the group consisting of (a) pyruvate dehydrogenase (E1), (b) dihydrolipoyl transacetylase, and (c) dihydrolipoyl dehydrogenase.

**[0122]** By using any of these methods, the recombinant microorganism can produce increased amounts of acetyl Co-A in comparison to microorganisms wherein the activity of pyruvate dehydrogenase is not modulated. Modulating the activity of pyruvate dehydrogenase can result in more carbon flux into the mevalonate dependent biosynthetic pathway in comparison to microorganisms that do not have modulated pyruvate dehydrogenase expression.

#### Combinations of Mutations

**[0123]** It is understood that for any of the enzymes and/or enzyme pathways described herein, molecular manipulations that modulate any combination (two, three, four, five or six) of the enzymes and/or enzyme pathways described herein is expressly contemplated. For ease of the recitation of the combinations, citrate synthase (gltA) is designated as A, phosphotransacetylase (ptaB) is designated as B, acetate kinase (ackA) is designated as C, lactate dehydrogenase (ldhA) is designated as D, malic enzyme (sfcA or maeB) is designated as E, and pyruvate decarboxylase (aceE, aceF, and/or lpdA) is designated as F. As discussed above, aceE, aceF, and/or lpdA enzymes of the pyruvate decarboxylase complex can be used singly, or two of three enzymes, or three of three enzymes for increasing pyruvate decarboxylase activity.

**[0124]** Accordingly, for combinations of any two of the enzymes A-F, non-limiting combinations that can be used are: AB, AC, AD, AE, AF, BC, BD, BE, BF, CD, CE, CF, DE, DF and EF. For combinations of any three of the enzymes A-F, non-limiting combinations that can be used are: ABC, ABD, ABE, ABF, BCD, BCE, BCF, CDE, CDF, DEF, ACD, ACE, ACF, ADE, ADF, AEF, BDE, BDF, BEF, and CEF. For combinations of any four of the enzymes A-F, non-limiting combinations that can be used are: ABCD, ABCE, ABCF, ABDE, ABDF, ABEF, BCDE, BCDF, CDEF, ACDE, ACDF, ACEF, BCEF, BDEF, and ADEF. For combinations of any five of the enzymes A-F, non-limiting combinations that can be used are: ABCDE, ABCDF, ABDEF, BCDEF, ACDEF, and ABCEF. In another aspect, all six enzyme combinations are used: ABCDEF.

[0125] Accordingly, the recombinant microorganism as described herein can achieve increased mevalonate production that is increased compared to microorganisms that are not grown under conditions of tri-carboxylic acid (TCA) cycle activity, wherein metabolic carbon flux in the recombinant microorganism is directed towards mevalonate production by modulating the activity of one or more enzymes from the group consisting of (a) citrate synthase, (b) phosphotransacetylase and/or acetate kinase, (c) lactate dehydrogenase, (d) malic enzyme, and (e) pyruvate decarboxylase complex.

#### Other Regulators and Factors for Increased Production

[0126] Other molecular manipulations can be used to increase the flow of carbon towards mevalonate and/or isoprene production. One method is to reduce, decrease or eliminate the effects of negative regulators for pathways that feed into the mevalonate pathway. For example, in some cases, the genes *aceEF-lpdA* are in an operon, with a fourth gene upstream *pdhR*. *pdhR* is a negative regulator of the transcription of its operon. In the absence of pyruvate, it binds its target promoter and represses transcription. It also regulates *ndh* and *cyoABCD* in the same way (Ogasawara, H. et al. 2007. J. Bact. 189:5534-5541). In one aspect, deletion of *pdhR* regulator can improve the supply of pyruvate, and hence the production of mevalonate and isoprene.

[0127] In other aspects, the introduction of 6-phosphogluconolactonase (PGL) into microorganisms (such as various *E. coli* strains) which lack PGL can be used to improve production of mevalonate and/or isoprene. PGL may be introduced using chromosomal integration or extra-chromosomal vehicles, such as plasmids.

#### *Exemplary Cell Culture Media and Conditions*

[0128] The invention also includes a cell or a population of cells in culture that produce isoprene. By “cells in culture” is meant two or more cells in a solution (*e.g.*, a cell medium) that allows the cells to undergo one or more cell divisions. “Cells in culture” do not include plant cells that are part of a living, multicellular plant containing cells that have differentiated into plant tissues. In various aspects, the cell culture includes at least or about 10, 20, 50, 100, 200, 500, 1,000, 5,000, 10,000 or more cells.

[0129] Carbon source that can be used to cultivate the host cells are described in WO 2009/076676, WO 2010/003007, and WO 2009/132220. In one aspect, the recombinant cells of the invention can be grown in a fed-batch culture at the 15-L scale using the following reagents:

[0130] 1000X Trace Metal Solution (per liter): Citric Acids \* H<sub>2</sub>O 40 g, MnSO<sub>4</sub> \* H<sub>2</sub>O 30 g, NaCl 10 g, FeSO<sub>4</sub> \* 7H<sub>2</sub>O 1 g, CoCl<sub>2</sub> \* 6H<sub>2</sub>O 1 g, ZnSO \* 7H<sub>2</sub>O 1 g, CuSO<sub>4</sub> \* 5H<sub>2</sub>O 100 mg, H<sub>3</sub>BO<sub>3</sub> 100 mg, NaMoO<sub>4</sub> \* 2H<sub>2</sub>O 100 mg. Each component was dissolved one at a time in Di H<sub>2</sub>O, pH was adjusted to 3.0 with HCl/NaOH, and then the solution was q.s. to volume and filter sterilized with a 0.22 micron filter.

[0131] Vitamin Solution (per liter): Thiamine hydrochloride 1.0 g, D-(+)-biotin 1.0 g, nicotinic acid 1.0 g, D-pantothenic acid 4.8 g, pyridoxine hydrochloride 4.0 g. Each component was dissolved one at a time in Di H<sub>2</sub>O, pH was adjusted to 3.0 with HCl/NaOH, and then the solution was q.s. to volume and filter sterilized with 0.22 micron filter.

[0132] Macro Salt Solution (per liter): MgSO<sub>4</sub> \* 7H<sub>2</sub>O 296 g, citric acid monohydrate 296 g, ferric ammonium citrate 49.6 g. All components were dissolved in water, q.s. to volume and filter sterilized with 0.22 micron filter.

[0133] Feed solution (per kilogram): Glucose 0.57 kg, Di H<sub>2</sub>O 0.38 kg, K<sub>2</sub>HPO<sub>4</sub> 7.5 g, and 100% Foamblast 10 g. All components were mixed together and autoclaved. Macro Salt Solution 11.1 mL, 1000X Trace Metal Solution 1.6 ml, Vitamin Solution 13.1 mL and 5.4 mL of a 350 g/L yeast extract solution (filter sterilized with 0.22 micron filter) were added after the solution had cooled to 25°C.

[0134] Phosphate Solution (per liter): KH<sub>2</sub>PO<sub>4</sub> 68 g, K<sub>2</sub>HPO<sub>4</sub> 68 g. All components were dissolved in water, q.s. to volume and autoclaved for 30 min.

[0135] Other methods and materials that can be used for culturing any of the recombinant cells herein is described in the Examples. Materials and methods suitable for the maintenance and growth of bacterial cultures are well known in the art. Exemplary techniques may be found in WO 2009/076676, WO 2010/003007, and WO 2009/132220, and



Manual of Methods for General Bacteriology Gerhardt *et al.*, eds), American Society for Microbiology, Washington, D.C. (1994) or Brock in Biotechnology: A Textbook of Industrial Microbiology, Second Edition (1989) Sinauer Associates, Inc., Sunderland, MA. In some aspects, the cells are cultured in a culture medium under conditions permitting the expression of one or both of the IspG enzymes, one or more isoprene synthase polypeptide, iron-sulfur cluster-interacting redox polypeptide, DXP pathway polypeptide, DXP pathway associated polypeptide, or IDI polypeptide encoded by a nucleic acid inserted into the host cells.

*Exemplary Methods for Decoupling Isoprene Production from Cell Growth.*

[0136] The recombinant cells of the invention can be grown in a way as to decouple the isoprene production from cell growth. When feedstock is used, it is desirable for the carbon from the feedstock to be converted to isoprene rather than to the growth and maintenance of the cells. In some aspects, the cells are grown to a low to medium OD<sub>600</sub>, then production of isoprene is started or increased. This strategy permits a large portion of the carbon to be converted to isoprene. One of skill in the art can grow the recombinant cells of the invention by following the teaching in WO 2010/003007.

[0137] In some aspects, isoprene is only produced in stationary phase. In some aspects, isoprene is produced in both the growth phase and stationary phase. In some aspects, isoprene is only produced in the growth phase. In some aspects, the nucleic acids encoding the various enzymes and polypeptides described herein are placed under the control of a promoter or factor that is more active in stationary phase than in the growth phase. For example, one or more isoprene synthase nucleic acid, iron-sulfur cluster-interacting redox nucleic acid, DXP pathway nucleic acid, DXP pathway associated nucleic acid, IspG enzymes and/or IDI nucleic acid may be placed under control of a stationary phase sigma factor, such as RpoS. In some aspects, one or more isoprene synthase nucleic acid, iron-sulfur cluster-interacting redox nucleic acid, DXP pathway nucleic acid, DXP pathway associated nucleic acid, IspG enzymes and/or IDI nucleic acid are placed under control of a promoter inducible in stationary phase, such as a promoter inducible by a response regulator active in stationary phase.

*Production of Isoprene within Safe Operating Ranges*

[0138] The production of isoprene using the recombinant cells disclosed herein can be done within safe operating levels according to its flammability characteristics, which simplifies the design and construction of commercial facilities, vastly improves the ability to operate safely, and limits the potential for fires to occur. In particular, the optimal ranges for the production of isoprene are within the safe zone, *i.e.*, the nonflammable range of isoprene concentrations. In one such aspect, the invention features a method for the production of isoprene within the nonflammable range of isoprene concentrations (outside the flammability envelope of isoprene). Safe operating ranges are described in WO 2010/003007 and the ranges disclosed therein are specifically incorporated by reference.

*Exemplary Production of Isoprene*

[0139] The invention provides, *inter alia*, compositions and methods for increasing the production of isoprene from cultured cells using two types of IspG enzymes, one or more DXP pathway enzymes and isoprene synthase, optionally in combination with iron-sulfur cluster-interacting redox genes or polypeptides and IDI genes and polypeptides. In some aspects, the recombinant cells produce a cumulative titer (total amount) of isoprene at greater than or about 1, 2, 3, 4, 5, 6, 7, 8, 8.4, 9, 10, 25, 50, 75, 100, 150, 175, or 200 g/ L<sub>broth</sub>. In some aspects, the upper limit is about 1, 2, 3, 4, 5, 6, 7, 8, 8.4, 9, 10, 25, 50, 75, 100, 150, 175, or 200 g/ L<sub>broth</sub>.

[0140] Various measurement for isoprene production (e.g., specific productivity of isoprene, instantaneous isoprene production rate in a fermentor, etc.) can be measured as disclosed in WO 2009/076676, WO 2010/003007, and WO 2009/132220.

[0141] In some aspects, the isoprene composition comprises greater than or about 99.90, 99.92, 99.94, 99.96, 99.98, or 100% isoprene by weight compared to the total weight of all C5 hydrocarbons in the composition. In some aspects, the composition has a relative detector response of greater than or about 99.90, 99.91, 99.92, 99.93, 99.94, 99.95, 99.96, 99.97, 99.98, 99.99, or 100% for isoprene compared to the detector response for all C5 hydrocarbons in the composition. In some aspects, the isoprene composition comprises

between about 99.90 to about 99.92, about 99.92 to about 99.94, about 99.94 to about 99.96, about 99.96 to about 99.98, about 99.98 to 100% isoprene by weight compared to the total weight of all C5 hydrocarbons in the composition.

**[0142]** In some aspects, the isoprene composition comprises less than or about 0.12, 0.10, 0.08, 0.06, 0.04, 0.02, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00005, or 0.00001% C5 hydrocarbons other than isoprene (such as 1,3-cyclopentadiene, *trans*-1,3-pentadiene, *cis*-1,3-pentadiene, 1,4-pentadiene, 1-pentyne, 2-pentyne, 3-methyl-1-butyne, pent-4-ene-1-yne, *trans*-pent-3-ene-1-yne, or *cis*-pent-3-ene-1-yne) by weight compared to the total weight of all C5 hydrocarbons in the composition. In some aspects, the composition has a relative detector response of less than or about 0.12, 0.10, 0.08, 0.06, 0.04, 0.02, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00005, or 0.00001% for C5 hydrocarbons other than isoprene compared to the detector response for all C5 hydrocarbons in the composition. In some aspects, the composition has a relative detector response of less than or about 0.12, 0.10, 0.08, 0.06, 0.04, 0.02, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00005, or 0.00001% for 1,3-cyclopentadiene, *trans*-1,3-pentadiene, *cis*-1,3-pentadiene, 1,4-pentadiene, 1-pentyne, 2-pentyne, 3-methyl-1-butyne, pent-4-ene-1-yne, *trans*-pent-3-ene-1-yne, or *cis*-pent-3-ene-1-yne compared to the detector response for all C5 hydrocarbons in the composition. In some aspects, the isoprene composition comprises between about 0.02 to about 0.04%, about 0.04 to about 0.06%, about 0.06 to 0.08%, about 0.08 to 0.10%, or about 0.10 to about 0.12% C5 hydrocarbons other than isoprene (such as 1,3-cyclopentadiene, *trans*-1,3-pentadiene, *cis*-1,3-pentadiene, 1,4-pentadiene, 1-pentyne, 2-pentyne, 3-methyl-1-butyne, pent-4-ene-1-yne, *trans*-pent-3-ene-1-yne, or *cis*-pent-3-ene-1-yne) by weight compared to the total weight of all C5 hydrocarbons in the composition.

**[0143]** In some aspects, the isoprene composition comprises less than or about 50, 40, 30, 20, 10, 5, 1, 0.5, 0.1, 0.05, 0.01, or 0.005 ug/L of a compound that inhibits the polymerization of isoprene for any compound in the composition that inhibits the polymerization of isoprene. In some aspects, the isoprene composition comprises between about 0.005 to about 50, such as about 0.01 to about 10, about 0.01 to about 5, about 0.01 to about 1, about 0.01 to about 0.5, or about 0.01 to about 0.005 ug/L of a compound that inhibits the polymerization of isoprene for any compound in the composition that inhibits the polymerization of isoprene. In some aspects, the isoprene composition comprises less than or about 50, 40, 30, 20, 10, 5,

1, 0.5, 0.1, 0.05, 0.01, or 0.005 ug/L of a hydrocarbon other than isoprene (such as 1,3-cyclopentadiene, *trans*-1,3-pentadiene, *cis*-1,3-pentadiene, 1,4-pentadiene, 1-pentyne, 2-pentyne, 3-methyl-1-butyne, pent-4-ene-1-yne, *trans*-pent-3-ene-1-yne, or *cis*-pent-3-ene-1-yne). In some aspects, the isoprene composition comprises between about 0.005 to about 50, such as about 0.01 to about 10, about 0.01 to about 5, about 0.01 to about 1, about 0.01 to about 0.5, or about 0.01 to about 0.005 ug/L of a hydrocarbon other than isoprene. In some aspects, the isoprene composition comprises less than or about 50, 40, 30, 20, 10, 5, 1, 0.5, 0.1, 0.05, 0.01, or 0.005 ug/L of a protein or fatty acid (such as a protein or fatty acid that is naturally associated with natural rubber).

**[0144]** In some aspects, the isoprene composition comprises less than or about 10, 5, 1, 0.8, 0.5, 0.1, 0.05, 0.01, or 0.005 ppm of alpha acetylenes, piperylenes, acetonitrile, or 1,3-cyclopentadiene. In some aspects, the isoprene composition comprises less than or about 5, 1, 0.5, 0.1, 0.05, 0.01, or 0.005 ppm of sulfur or allenes. In some aspects, the isoprene composition comprises less than or about 30, 20, 15, 10, 5, 1, 0.5, 0.1, 0.05, 0.01, or 0.005 ppm of all acetylenes (such as pentyne-1, butyne-2, 2MB1-3yne, and 1-pentyne-4yne). In some aspects, the isoprene composition comprises less than or about 2000, 1000, 500, 200, 100, 50, 40, 30, 20, 10, 5, 1, 0.5, 0.1, 0.05, 0.01, or 0.005 ppm of isoprene dimers, such as cyclic isoprene dimmers (*e.g.*, cyclic C10 compounds derived from the dimerization of two isoprene units).

**[0145]** In some aspects, the composition comprises greater than about 2 mg of isoprene, such as greater than or about 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 mg of isoprene. In some aspects, the composition comprises greater than or about 2, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 g of isoprene. In some aspects, the amount of isoprene in the composition is between about 2 to about 5,000 mg, such as between about 2 to about 100 mg, about 100 to about 500 mg, about 500 to about 1,000 mg, about 1,000 to about 2,000 mg, or about 2,000 to about 5,000 mg. In some aspects, the amount of isoprene in the composition is between about 20 to about 5,000 mg, about 100 to about 5,000 mg, about 200 to about 2,000 mg, about 200 to about 1,000 mg, about 300 to about 1,000 mg, or about 400 to about 1,000 mg. In some aspects, greater than or about 20, 25, 30, 40, 50, 60, 70, 80, 90, or 95% by weight of the volatile organic fraction of the composition is isoprene.

*Exemplary Isoprene Purification Methods*

[0146] In some aspects, any of the methods described herein further include recovering the isoprene. For example, the isoprene produced using the compositions and methods of the invention can be recovered using standard techniques, such as gas stripping, membrane enhanced separation, fractionation, adsorption/desorption, pervaporation, thermal or vacuum desorption of isoprene from a solid phase, or extraction of isoprene immobilized or absorbed to a solid phase with a solvent (see, for example, U.S. Patent Nos. 4,703,007 and 4,570,029, which are each hereby incorporated by reference in their entireties, particularly with respect to isoprene recovery and purification methods). In one aspect, the isoprene is recovered by absorption stripping (*see, e.g.*, US Pub. No. 2011/0178261). In particular, aspects, extractive distillation with an alcohol (such as ethanol, methanol, propanol, or a combination thereof) is used to recover the isoprene. In some aspects, the recovery of isoprene involves the isolation of isoprene in a liquid form (such as a neat solution of isoprene or a solution of isoprene in a solvent). Gas stripping involves the removal of isoprene vapor from the fermentation off-gas stream in a continuous manner. Such removal can be achieved in several different ways including, but not limited to, adsorption to a solid phase, partition into a liquid phase, or direct condensation (such as condensation due to exposure to a condensation coil or do to an increase in pressure). In some aspects, membrane enrichment of a dilute isoprene vapor stream above the dew point of the vapor resulting in the condensation of liquid isoprene. In some aspects, the isoprene is compressed and condensed.

[0147] The recovery of isoprene may involve one step or multiple steps. In some aspects, the removal of isoprene vapor from the fermentation off-gas and the conversion of isoprene to a liquid phase are performed simultaneously. For example, isoprene can be directly condensed from the off-gas stream to form a liquid. In some aspects, the removal of isoprene vapor from the fermentation off-gas and the conversion of isoprene to a liquid phase are performed sequentially. For example, isoprene may be adsorbed to a solid phase and then extracted from the solid phase with a solvent. In one aspect, the isoprene is recovered by using absorption stripping as described in U.S. Appl. No. 12/969,440 (US Publ. No. 2011/0178261).

[0148] In some aspects, any of the methods described herein further include purifying the isoprene. For example, the isoprene produced using the compositions and methods of the invention can be purified using standard techniques. Purification refers to a process through which isoprene is separated from one or more components that are present when the isoprene is produced. In some aspects, the isoprene is obtained as a substantially pure liquid. Examples of purification methods include (i) distillation from a solution in a liquid extractant and (ii) chromatography. As used herein, “purified isoprene” means isoprene that has been separated from one or more components that are present when the isoprene is produced. In some aspects, the isoprene is at least about 20%, by weight, free from other components that are present when the isoprene is produced. In various aspects, the isoprene is at least or about 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90%, 95%, or 99%, by weight, pure. Purity can be assayed by any appropriate method, *e.g.*, by column chromatography, HPLC analysis, or GC-MS analysis.

[0149] In some aspects, at least a portion of the gas phase remaining after one or more recovery steps for the removal of isoprene is recycled by introducing the gas phase into a cell culture system (such as a fermentor) for the production of isoprene.

## EXAMPLES

[0150] The examples, which are intended to be purely exemplary of the invention and should therefore not be considered to limit the invention in any way, also describe and detail aspects and aspects of the invention discussed above. Unless indicated otherwise, temperature is in degrees Centigrade and pressure is at or near atmospheric. The foregoing examples and detailed description are offered by way of illustration and not by way of limitation. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

**Example 1: Generation of Ptac Anabaena ispH-T elong ispG system aspA term/pEWL454**

*Cloning of the T. elongatus IspG system into Ptac Anabaena ispH aspA term/pEWL454*

[0151] A DNA sequence harboring the *T. elongates* IspG system consisting of gcpE-petF-petH present in plasmid Ptac-gcpE-petF-petH/pK184 has been described previously (see U.S. Pat. Appl. Ser. No. 12/817,134 (US Publ. No. 2011/0014672), Example 9). Using DNA Polymerase I (Large Klenow Fragment), BamHI, and PstI (New England BioLabs, MA) a 5' blunt (BamHI destroyed) – 3' PstI gcpE-petF-petH fragment was obtained. The Ptac Anabaena ispH aspA term/pEWL454 vector was digested with SmaI and PstI (New England BioLabs, MA) according to the manufacturer's suggested protocol. The SmaI and PstI cut Ptac Anabaena ispH aspA term/pEWL454 DNA was combined with the final digest reaction harboring the 5' blunt (BamHI destroyed) - gcpE-petF-petH - 3' PstI fragment and the DNA mixture cleaned using a Qiagen QiaQuick Gel Extraction Kit. Approximately one half of the cleaned cut DNA was ligated using T4 DNA Ligase (New England Biolabs, MA) according to the manufacturer's suggested protocol. A portion of the ligation was used to transform strain MD09-220, previously described in U.S. Pat. Appl. Ser. No. 12/817,134 (US Publ. No. 2011/0014672), example 11, by electroporation methods. The Bio Rad Gene Pulser system (Bio-Rad, CA) with a 0.1 cm cuvette, cat. # 165-2089, and a transformation protocol suggested by the manufacturer was used. Transformants were recovered in LB broth plus 500uM mevalonic acid for 1 hour at 37°C before plating onto LB agar containing kanamycin (50ug/ml) without mevalonic acid. Only transformants harboring a functionally expressed *ispH* allele were expected to form colonies. Kanamycin resistant colonies were selected for verification of the gcpE-petF-petH insert as follows:

[0152] A polymerase chain reaction (PCR) assay was setup by preparation of the following mixture;

0.5µl template (approx. 0.5ul volume of colony cells)

16.25 µl diH<sub>2</sub>O

0.25µl dNTP's (100 mM)

0.625µl primer (10uM) 5' top Te gcpE seq primer

0.625µl primer (10uM) 5' NdeI F- T.e. gcpE pET-15b

0.625µl primer (10uM) 3' bottom Te gcpE seq primer  
0.625µl primer (10uM) 3' BamHI R- T.e. gcpE pET-15b  
5.0µl *HerculaseII* Buffer  
0.5µl of *HerculaseII fusion* (Stratagene, CA)  
25µl total volume

[0153] The PCR reaction was run on a Biometra T3000 Combi Thermocycler (Biometra, Germany) using the following cycle parameters: 95°C x 2min., (95°C x 30sec., 55°C x 30sec., 72°C x 1 min.) x 29 cycles; 72°C x 5 min., 4°C until cool.

[0154] Primer sequences were as follows;

[0155] 5' top Te gcpE seq primer: 5' - cacttgagtttatacgcac

[0156] 3' bottom Te gcpE seq primer: 5' - gatgcgtataaactcaagt

[0157] 5' NdeI F- T.e. gcpE pET-15b: 5' - gcggcagccatagcaaacgttgccaagccca

[0158] 3' BamHI R- T.e. gcpE pET-15b: 5' - tagcagccggatccttatggatctacctacc

[0159] The resulting PCR fragments were separated on a 1.2% E-gel (Invitrogen, CA). Colonies from which a PCR product(s) of anticipated size was observed were considered positive for the gcpE-containing insert and processed further.

[0160] Kanamycin resistant colonies from which a successful fragment of gcpE was amplified were grown overnight in LB broth containing kanamycin (50ug/ml), and harvested for subsequent plasmid preparation. Plasmid constructs were isolated using Qiagen Qiaprep Spin Miniprep Kit (Qiagen, CA). Plasmid preparations of interest were sequenced (Sequetech, CA) using primers M13-65 (5' - AGGCGATTAAGTTGGGTA) and pSE3805 (5' - GGCTCGTATAATGTGTGG) to further verify insertion of the gcpE-petF-petH sequence into Ptac *Anabaena ispH aspA term/pEWL454*, with the resulting plasmid construct



now referred to as Ptac Anabaena ispH-T elong ispG system aspA term/pEWL454 (see Figure 1). A correct Ptac Anabaena ispH-T elong ispG system aspA term/pEWL454 clone was identified and was designated as strain REM I6\_17.

### **Example 2: Generation of the enhanced DXP flux isoprene producing strain REM F2\_18**

*Transformation of REM I7\_11 with Ptac Anabaena ispH-T elong ispG system aspA term/pEWL454*

[0161] The isoprene producing parental strain REM I7\_11 was described previously (see U.S. Pat. Appl. Ser. No. 12/817,134 (US Publ. No. 2011/0014672), Example 29). In addition to increased expression from chromosomally encoded DXP pathway genes *dxs* and *dxr*, the REM I7\_11 strain harbors plasmid encoded copies of both *fldA* and *ispG* as well as the *fldA* and *ispG* loci present within the BL21 genome. The Ptac Anabaena ispH-T elong ispG system aspA term/pEWL454 plasmid was introduced by electroporation into strain REM I7\_11. Electroporation was performed using a Bio-Rad Gene Pulser system with a 0.1 cm cuvette, cat.# 165-2089. Transformation was achieved by following the manufacturer's suggested protocol. Transformants were recovered in LB broth for 1 hour at 37°C before plating onto LB agar containing spectinomycin (50ug/ml), carbenicillin (50ug/ml), and kanamycin (50ug/ml). The resulting strain was named REM F2\_18.

### **Example 3: Large scale fermentation of REM F2\_18 yielding an 8.4g/L isoprene titer**

[0162] Isoprene production from *E. coli* cells expressing genes from the DXP pathway and isoprene synthase were grown in fed-batch culture at the 15-L scale using the following reagents;

[0163] 1000X Trace Metal Solution (per liter): Citric Acids \* H<sub>2</sub>O 40 g, MnSO<sub>4</sub> \* H<sub>2</sub>O 30 g, NaCl 10 g, FeSO<sub>4</sub> \* 7H<sub>2</sub>O 1 g, CoCl<sub>2</sub> \* 6H<sub>2</sub>O 1 g, ZnSO \* 7H<sub>2</sub>O 1 g, CuSO<sub>4</sub> \* 5H<sub>2</sub>O 100 mg, H<sub>3</sub>BO<sub>3</sub> 100 mg, NaMoO<sub>4</sub> \* 2H<sub>2</sub>O 100 mg. Each component was dissolved one at a time in Di H<sub>2</sub>O, pH was adjusted to 3.0 with HCl/NaOH, and then the solution was q.s. to volume and filter sterilized with a 0.22 micron filter.

[0164] Vitamin Solution (per liter): Thiamine hydrochloride 1.0 g, D-(+)-biotin 1.0 g, nicotinic acid 1.0 g, D-pantothenic acid 4.8 g, pyridoxine hydrochloride 4.0 g. Each component was dissolved one at a time in Di H<sub>2</sub>O, pH was adjusted to 3.0 with HCl/NaOH, and then the solution was q.s. to volume and filter sterilized with 0.22 micron filter.

[0165] Macro Salt Solution (per liter): MgSO<sub>4</sub> \* 7H<sub>2</sub>O 296 g, citric acid monohydrate 296 g, ferric ammonium citrate 49.6 g. All components were dissolved in water, q.s. to volume and filter sterilized with 0.22 micron filter.

[0166] Feed solution (per kilogram): Glucose 0.57 kg, Di H<sub>2</sub>O 0.38 kg, K<sub>2</sub>HPO<sub>4</sub> 7.5 g, and 100% Foamblast 10 g. All components were mixed together and autoclaved. Macro Salt Solution 11.1 mL, 1000X Trace Metal Solution 1.6 mL, Vitamin Solution 13.1 mL and 5.4 mL of a 350 g/L yeast extract solution (filter sterilized with 0.22 micron filter) were added after the solution had cooled to 25°C.

[0167] Phosphate Solution (per liter): KH<sub>2</sub>PO<sub>4</sub> 68 g, K<sub>2</sub>HPO<sub>4</sub> 68 g. All components were dissolved in water, q.s. to volume and autoclaved for 30 min.

[0168] Fermentation was performed in a 15-L bioreactor with the F2\_18 strain; *E. coli* BL21 cells over expressing the first two enzymes in the dxp pathway (PL.6-dxs and G11.6-dxr), the last enzyme in the DXP pathway (G11.6-yIDI), other genes involved in the DXP pathway (G11.6-fldA-ispG/pCL, PTac-Anabaena ispH-T.elong.gcpE-petF-petH aspA term/pEWL454), the lower MVA pathway (PL.2-mKKDyI), truncated isoprene synthase from *P. alba* (pDW33, see U.S. Publ No. 2011/0014672), and containing a restored chromosomal *pgl* gene (t ybgS::Kan or t ybgS::frit). This experiment was carried out at pH 7.0 and 34°C. Truncated isoprene synthase is also described in US Patent Publication No. 2010/0003716.

[0169] A frozen vial of the *E. coli* strain was thawed and inoculated into tryptone-yeast extract medium for the bioreactor. After the culture grew to optical density 1.0, measured at 550 nm (OD<sub>550</sub>), 500 mL was used to inoculate a 15-L bioreactor and bring the initial tank volume to 5 L. Carbenicillin, spectinomycin and kanamycin were each present at a concentration of 50 ug/mL, respectively, in the seed flask and fermentation tank.

[0170] Once the batch glucose was depleted, the glucose feed solution was fed at an exponential rate from 0.35 g/min until the feed rate reached 2.72 g/min. This was immediately followed by a linear ramp that lasted the duration of the fermentation and brought the feed rate up to 4.225 g/min at 68 h. The total amount of glucose delivered to the bioreactor during the 68 hr fermentation was 3.5 kg.

[0171] The phosphate solution described above was fed at 0.21 g/min starting at a carbon dioxide evolution rate (CER) of 50 mmol/L/h, and at 16 h feed time, was stepped down to 0.11g/min and fed for the duration of the experiment.

[0172] Induction was achieved by adding isopropyl-beta-D-1-thiogalactopyranoside (IPTG) from a 10 mg/mL stock. At time zero, 3 mL was added (25 uM). Subsequent additions were at a carbon dioxide evolution rate (CER) of 25 mmol/L/h (3 mL), CER of 50 mmol/L/h (6 mL), CER of 100 mmol/Lh (6 mL) and CER of 150 mmol/L/h (3 mL).

[0173] The isoprene level in the off-gas from the bioreactors was determined using a Hiden Analytical mass spectrometer (Livonia, Michigan, USA). Calibration of the instrument was done with an isoprene calibration standard supplied by Precision Gas Products Inc. (Mississauga, Ontario, Canada). The isoprene titer increased over the course of the fermentation to a maximum value of 8.4 g/L at 68 hr (see Fig. 2 and 4).

[0174] Equation for calculating Isoprene Titer:

[0175]  $\int$ (Instantaneous isoprene production rate, g/L/hr)dt from t = 0 to 68 hrs [=] g/L broth

Sequence of plasmid Ptac Anabaena ispH-T elong ispG system aspA term/pEWL454

[0176] cgataagctagcttcacgctgccgcaagcactcagggcgcaagggctgctaaaggaagcggaacacgtagaaagcagctccgagaaacgggtgctgaccccgatgaatgtcagctactgggctatctggacaagggaaaacgcaagcgcaaagagaaagcaggtagcttgcaagtgggcttacatggcgatagctagactggcggtttatggacagcaagcgaaccggaattgccagctggggcgccctctggtaaaggttgggaagccctgcaaagtaaactggatggctttctgccccaaggatctgatggcgaggggatcaagatctgatcaagagacaggatgaggatcgtttcgcattgattgaacaagatggattgcacgcaggttctccggccgcttgggtggagaggctatt

cggtatgactgggcacaacagacaatcggtgctctgatgccgccgtgtccggctgtcagcgcagggcgcccggttctttgtca  
agaccgacctgtccgggtgccctgaatgaactccaagacgaggcagcgcggctatcgtggctggccacgacgggcgttccttgcgca  
gctgtgctcagctgtcactgaagcgggaaggactggctgctattgggcgaagtccggggcaggatctcctgtcatctcacctg  
ctcctgccgagaaagtatccatcatggctgatgcaatgcggcggtgcatacgttgatccggctacctgcccattcgaccaccaagc  
gaaacatcgcacgagcgcagcactcggatggaagccggctctgtcagcagcagcagcagcagcagcagcagcagcagcagcagc  
cgccagccgaactgttcgcaaggctcaaggcgcggatgcccagcgcgagcagcagcagcagcagcagcagcagcagcagcagc  
aatacatggtggaaaatggccgctttctggattcatcactgtggccggctgggtgtggcggaccgctatcaggacatagcgttggc  
taccctgtatattgtgaagagcttggcggcgaatgggctgaccgcttctcctgtgctttacggatcggcgtcccgttcgagcgc  
cgcttctatcgccttctgacgagttcttctgagcgggactctggggttcggatgataaagcgtgcaaacatgagaattacaacttatcg  
tatggggctgacttcaggtgctacattgaagagataaattgcaactgaaatctagaatattttatctgattaataagatgatcttctgagat  
cgtttggctcgcgtaatcttctgctctgaaaacgaaaaaccgcttgcaggcgggttttcgaaaggctctgagctaccaactctt  
gaaccgaggtactgcttggaggcgcagtcacaaaactgtcctttcagtttagccttaaccggcgcagcacttcaagactaact  
cctctaaatcaattaccagtggtgctgctgccagtggtgcttttgcagctcttccgggttgactcaagcagatagttaccggataaggcgc  
agcggctcggactgaacggggggttcgtgcatacagtcagcttggagcgaactgcctaccgggaactgagtgtaggcgtggaatg  
agacaaacgcggccataacagcgggaatgacaccggtaaaccgaaaggcaggaacaggagagcgcacgaggagccgccaggg  
ggaaacgcctggtatctttatagctctgctgggttcgccaccactgattgagcgtcagattcgtgatgcttgcagggggcggagc  
ctatggaaaaacgcttgcctcctgcgttatcccctgattctgtgataaccgtattaccgctttgagtgagctgataccgctcggcgc  
agccgaacgaccgagcgcagc  
gcccattcattaatgcagctggcacgacagggttcccactggaaaggaaattctgtgacaattaatcagcgtctgataatgtgtgaa  
ttgtgagcggataacaattcagcaggaacagattaccggatccctggagtttaaacatattgatactaaaacctttaaactgacgttgc  
aacactccgaaaactacaatcggaaagggttcggctatcagcgggaggttcaactcaactgcaatcagaatcagagttcttggattc  
aggaaatccgcgatcgaactacactctcaacgtgggatgtcacgataagacttgcagcagcatttggcttctgctgggggttgaac  
gtgcggctcgcgatggcttatgagaccgggaagcattttcaactgaacgcacatctggattaccaacgaaatcattcacaatccgagcgtc  
aaccagcggatgcaggaaatgcaagtggccttataccagtagaggcgggcaacaaggattttagcgtagtcggcaataatgacgtc  
gttatcctgccagccttggcgttctgtgcaagagatgcagctttatctgaaaaaggatgtaaaatagttgataccacatgtccgtgggt  
atcaaaagtctggaataccgtggaagcataaaaaagggggatcacaacctataatacatggcaataataaacacgaagaaacgatt  
gccacaagttccttcgggtaaatatctcatcgtccttaaccttaaggaaagcacaatacgttgctgactacattctgcatgggggtaac  
gtgaggagttcttacagaaattgcaaaagcatgctcggcgggctttgacccgatagagatcttgaagagttggcattgccaatcag  
acaacaatgtgaaaggagagaccgaacagatcggtaaacttttgaacataccatgctgcaaaaatacggaccgtggagttaaatca  
acatttctcagctcctcaatacaatttgcgacgctaccaggaacggcagcagcagcagcagcagcagcagcagcagcagcagcagc  
gatcgtgatcggaggtttaattctccaacacaacagctccaacagattagccaggaacggggtctgccgtcctatcatattgatga  
gttgagcgtatataaaagcataaactcgaatagagcaccggcagttaaacggagagttggtcactacggaaaattggctgcctcgggca  
aaattgtcgtaggtgtaacaagtggcgcgagtacaccagataagggtggtgaaagcgtgatcgaagagatcttgccttaaagcaaca  
gcggccgcttttaaccgatccattgaggagtaagccatgcaaacgttgcaagcccagttcaagctacaccaacggaacagcgtat

ttttagacgcaaaacccgcccggtccgataggtccgtttgttattgggtggcggccatcccgtggtgttcagtcfaatgattaacgaaga  
 cactctggatcgaaggttctgttctgcaattcggcgcttacacgagatcggttgcgagatctacgtgtgactgtaccttcattagca  
 cacgcgaaaagcaatggaagagattcgggatcggctttataaaacgtacaaaccggtccccttagttgccgacgtgcatcataacggaa  
 tgaaaatcgcgttagaggttgccaagtacgtggacaatgtgcgattaatcctggattatacgtgtttgagaagccaaaacaaatcgca  
 cggagtacactcaagctgaattgacgagattggcgcgaaaatccgtgaaacgttgaaccactggtaattcactgcgggatcaggg  
 aaagtcgatgcgcattggcgtaatacatggcagctctggcggaacggatgctgtttacctatggcgataccccagagggtatggtagag  
 agtgcacttgagttatagcatctgtgaaagtctcaactctataacttagaaattcccttaaagctagccgcgtcccgttatgatagcc  
 gccaatcggcttatggttaagcgcattggacgagctgggtatggattatccgttgcattcggagtactgaggcagggtgatggtgaata  
 tggccgtattaaaagcacagcaggcattgcaacactgctggcggaaggaattggagacacaatccgtgtttcattgactgaagctccg  
 gaaaaggaaatccccgtgtgctatggcatcctcaagccctcggctccgccaccatggtagaatatgtagcttcccgtcgtgtgg  
 tcggacattgttaacctggaagaggttctgcacaaggtgagagaagcgactaaacacctgacgggactgaatattgcggttatgggat  
 gtattgtaaatggacctggcgaaatggccgatgcagactacggctatgtaggtaaacagccgggatataatagctttaccggccg  
 ggaagaagtcaagaaagtccccgaggccgagggcggttgcagctctggtcgaactgataaaagcggatggtatggttagatccat  
 aagtggagctccccgtaccgtggacgaggtttaatggcgacgtataaagtcacactggtccgtccggatggcagcgaacgacc  
 atcgatgttccggaggacgaatacactggatgtcgggaagaacaaggtctggatctcccgtttctgtcgcgccggtgcctgctct  
 acctgtgctggcaaatgttggagggagaagtcgatcaaaagcaccagagcttcttggatgacgatcagatcgaaaaaggattcgtgc  
 ttacttgtgtggcctacccccgttcggactgcaagatctgacgaaccaagaggaggactgtactaagaggtcagcagcgcattgcaat  
 aacagaggttagtatgtataatgccactaactctcgtcacgtatgttccgggtacgaagttgtggggctgcgccaacggcggagacg  
 gagaaaacaatactcgcgatcagaaactctggctcgcagttctttaatgtgccttatgaccgcatgaaccagtttatgcagcagatcactc  
 ggtggggcggtaaaattgtcagattcagccccctaacggaaccgtggccccacttgcgaaccacggagccagctgccaataacg  
 gagctgcacctgtgaaagaaaagaaagtcgatataccgggtcaacatctaccgtccaataatccctgcataaggtatgcaac  
 gaggaactggtccgggaagcgggtgagggtacgggtgaaacatattatctttgatatacggggaccgaattacgttacttgaagggc  
 agtcaatcggatcattcccggggcacggacgcgaacggtaaaccacataagctgcgtctgtattccattgctccacaagacatggt  
 gactttcagatgacaagacgggtgccttatgcgtacggagattagaatacaagataaagagaccggggagaccatttatggcgtgt  
 gcagttcgtatcttaacagttacgcctggagatgaagtcaaaatcacaggtcctgttgggaaagaaatgcttctctgacgaccag  
 aagcgaactattatgctggctaccggcactggaatagcgcatttcgggcattttatggcggatgttcaaagagaacaacccggatt  
 accagttcaaagccttgcgtggtgttctttggcgtcgttatactgccaatatcctgtataaggacgagcttgaagctatccaagccca  
 gtatcccgatcatttcggttaacctacgcgatttcccgtgaacaaaaaccccgacggagggaaaatgtacatccagggctcggatcg  
 cagagcacgctgatgaaatctggcaactgctgcaaaaagaaaaaccccacgtgtacatgtgtggcctgcgtgggatggaacctggaa  
 tagacgagggccatgaccgcagcggccgcgaaaaacggagctgactggcaggagttctgaaaggtacgctgaaaaaggaaggca  
 gatggcatgtcgaacttattaactgcagtacaataaaaaaggcacgtcagatgacgtgcctttttctgaagcttggcactggccgtc  
 gttttacaacgtcgtgactgggaaaacctggcgttacccttaactgccttgcagcacatcccccttccagctggcgtaatagc  
 gaagaggcccgcaccgatcgccttcccaacagtgcgcagcctgaatggcgaatggcg

**Example 4: Large scale fermentation of REM H8\_12**

[0177] A plasmid-encoded *E. coli* IspG system (GI1.6-fldA-ispG/pCL) is combined with a plasmid-encoded *T. elongatus* IspG system (PTac-gcpE-petF-petH/pK185) into a DXP host strain. Comparisons are done for isoprene production at the 14-L scale using comparable fermentation processes to the *E. coli* IspG system alone strain REM H8\_12 (control). Without being bound by theory, if the IspG activity is enhanced over the control strain and IspH activity is not limiting, then higher isoprene titer is generated by the combined *E. coli* and *T. elongatus* IspG systems strain.

[0178] Compatible expression constructs are generated using standard molecular biology techniques in order to accommodate the additional heterologous IspH enzyme expressed in this particular background while maintaining similar antibiotic resistance genes to the control strain as well as keeping a comparable copy-number of the genes of interest. The genes encoding the *T. elongatus* IspG system are combined with the gene encoding the additional heterologous IspH enzyme into one operon harbored on a pK184 vector derivative, pEWL454. This results in the vector construct PTac-Anabaena ispH-T. elong IspG system/pEWL454, kanamycin resistant.

[0179] The relevant test strain, REM F2\_18, has the genotype: BL21 pgl+ PL.2-lower MVA pathway GI1.6-yidi PL.6-dxs GI1.6-dxr + GI1.6-fldA-ispG/pCL (Spec 50) + PTac-Anabaena ispH-T. elong IspG system/pEWL454 (Kan 50) + PTrc-truncated alba IspS/pTrc His (Carb 50). The control strain is: BL21 pgl+ PL.2-lower MVA pathway GI1.6-yidi PL.6-dxs GI1.6-dxr + GI1.6-fldA-ispG/pCL (Spec 50) + PTac Anabaena ispH /pK184 (Kan 50) + PTrc-truncated alba IspS/pTrc His (Carb 50).

**Example 5: Altering IspG levels for enhanced *In Vivo* activity**

[0180] The expression of the *E. coli* IspG system is increased to levels greater than that in the current *E. coli* IspG system isoprene producing strain (control). The two strains are compared for isoprene production. Without being bound by theory, if the IspG activity is enhanced over the control strain and IspH activity is not limiting, then a higher isoprene titer is generated by the enhanced *E. coli* IspG system strain.

[0181] In order to increase the expression of the *E. coli* IspG system, molecular biology methods are used to either increase the expression of the *E. coli* IspG system from its current vector construct (pCL based vector) by increasing the promoter strength that governs the expression level of the system (for example, changing the high constitutive GI1.6 promoter of the current system to the stronger constitutive PL.6 promoter) or by moving the current *E. coli* IspG system to a higher-copy vector (pBBR1MCS-5 vector, gentamicin resistance encoded, compatible with other vectors required for a comparable high DXP flux strain).

[0182] The relevant increased promoter strength test strain has the genotype: BL21 pgl+ PL.2-lower MVA pathway GI1.6-yidi PL.6-dxs GI1.6-dxr + PL.6-fldA-ispG/pCL (Spec 50) + PTac Anabaena ispH /pK184 (Kan 50) + PTrc-truncated alba IspS/pTrc His (Carb 50). The relevant increased vector copy-number test strain proposed has the genotype: BL21 pgl+ PL.2-lower MVA pathway GI1.6-yidi PL.6-dxs GI1.6-dxr + GI.6-fldA-ispG/pBBR1MCS-5 (Gent 10) + PTac Anabaena ispH /pK184 (Kan 50) + PTrc-truncated alba IspS/pTrc His (Carb 50). An additional increased vector copy-number test strain proposed has the genotype: BL21 pgl+ PL.2-lower MVA pathway GI1.6-yidi PL.6-dxs GI1.6-dxr + GI.6-fldA-ispG/pCL (Spec 50) + GI.6-fldA-ispG/pBBR1MCS-5 (Gent 10) + PTac Anabaena ispH /pK184 (Kan 50) + PTrc-truncated alba IspS/pTrc His (Carb 50). The control strain is BL21 pgl+ PL.2-lower MVA pathway GI1.6-yidi PL.6-dxs GI1.6-dxr + GI1.6-fldA-ispG/pCL (Spec 50) + PTac Anabaena ispH /pK184 (Kan 50) + PTrc-truncated alba IspS/pTrc His (Carb 50).

[0183] Without being bound by theory, with respect to IspH activity not being limiting, as described above, IspH activity in existing *E. coli* IspG system and *T. elongatus* IspG system isoprene producing strains does not appear limiting. To determine insufficient an IspH activity level that would hamper isoprene output and confound the interpretation of any effects on IspG activity, one of skill in the art looks for the phenotypes described above and use biochemical assays. In the absence of any indication that IspH activity is limiting, isoprene production is used as a means to reflect improved IspG activity. IspG levels can be determined by immunoblot to confirm expression levels associated with the measured activities.

## CLAIMS

What is claimed is:

1. A recombinant cell capable of producing isoprene, the cell transformed with: (i) a nucleic acid encoding a first 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate synthase (IspG) polypeptide of a first species; (ii) a nucleic acid encoding a second IspG polypeptide of a second species, wherein the second species differs from the first species; (iii) a nucleic acid encoding at least one DXP pathway enzyme and (iv) a nucleic acid encoding an isoprene synthase polypeptide.
2. The recombinant cell of claim 1, wherein the first IspG polypeptide is a *T. elongatus* IspG polypeptide.
3. The recombinant cell of claim 1, wherein the second IspG polypeptide is an *E. coli* IspG polypeptide.
4. The recombinant cell of claim 1, further comprising a nucleic acid encoding an iron-sulfur cluster-interacting redox polypeptide.
5. The recombinant cell of claim 4, wherein the iron-sulfur cluster-interacting redox polypeptide is selected from ferredoxin and flavodoxin.
6. The recombinant cell of claim 1, further comprising a nucleic acid encoding a DXP pathway associated polypeptide.
7. The recombinant cell of claim 6, wherein the DXP pathway associated polypeptide polypeptide is a chaperone protein.
8. The recombinant cell of claim 1, wherein the cell further comprises at least one heterologous nucleic acid encoding an isopentenyl-diphosphate delta-isomerase (IDI) polypeptide or at least one copy of an endogenous nucleic acid encoding an IDI polypeptide.
9. The recombinant cell of claim 1, wherein the cell further comprises at least one heterologous nucleic acid encoding a MVA pathway polypeptide or at least one copy of an endogenous nucleic acid encoding a MVA pathway polypeptide.



10. The recombinant cell of claim 8, wherein the cell further comprises at least one heterologous nucleic acid encoding a MVA pathway polypeptide or at least one copy of an endogenous nucleic acid encoding a MVA pathway polypeptide.
11. The recombinant cell of claim 1, wherein the isoprene synthase polypeptide is a plant isoprene synthase polypeptide.
12. The recombinant cell of claim 11, wherein the isoprene synthase polypeptide is a polypeptide from *Pueraria* or *Populus* or a hybrid, *Populus alba* x *Populus tremula*.
13. The recombinant cell of claim 11, wherein the isoprene synthase polypeptide is selected from the group consisting of *Pueraria montana* or *Pueraria lobata*, *Populus tremuloides*, *Populus alba*, *Populus nigra*, and *Populus trichocarpa*.
14. The recombinant cell of claim 11, wherein the plant isoprene synthase polypeptide is a kudzu isoprene synthase polypeptide.
15. The recombinant cell of claim 1, wherein the cell is a bacterial, algal, fungal or yeast cell.
16. The recombinant cell of claim 15, wherein the cell is a bacterial cell.
17. The bacterial cell of claim 16, wherein the bacterial cell is a gram-positive bacterial cell or gram-negative bacterial cell.
18. The bacterial cell of claim 17, wherein the bacterial cell is selected from the group consisting of *E. coli*, *P. citrea*, *B. subtilis*, *B. licheniformis*, *B. lentus*, *B. brevis*, *B. stearothermophilus*, *B. alkalophilus*, *B. amyloliquefaciens*, *B. clausii*, *B. halodurans*, *B. megaterium*, *B. coagulans*, *B. circulans*, *B. lautus*, *B. thuringiensis*, *S. albus*, *S. lividans*, *S. coelicolor*, *S. griseus*, *Pseudomonas sp.*, and *P. alcaligenes* cells.
19. The bacterial cell of claim 18, wherein the bacterial cell is an *E. coli* cell.
20. The recombinant cell of claim 1, wherein the additional DXP pathway enzyme is selected from the group of DXS, DXR, MCT, CMK, MCS, HDR (IspH), and IDI.

21. The recombinant cell of claim 20, wherein the additional DXP pathway enzyme is selected from the group of DXS, DXR, HDR (IspH), and IDI.
22. A cell culture comprising the recombinant cell of claim 1, wherein the cell culture produces at least about 8.4 g/l of isoprene.
23. A cell culture comprising the recombinant cell of claim 10, wherein the cell culture produces at least about 8.4 g/l of isoprene.
24. A method of producing isoprene, the method comprising: (a) culturing the recombinant cell of claim 1 under conditions suitable for producing isoprene and (b) producing isoprene.
25. The method of claim 24, further comprising recovering the isoprene.
26. The method of claim 24, wherein the recombinant cell produces greater than about 8.4 g/l of isoprene.
27. A method of producing isoprene, the method comprising: (a) culturing the recombinant cell of claim 10 under conditions suitable for producing isoprene and (b) producing isoprene.
28. The method of claim 27, further comprising recovering the isoprene.
29. The method of claim 27, wherein the recombinant cell produces greater than about 8.4 g/l of isoprene.